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The rapid pace of drug development in recent years has led to the recognition that new
pharmacotherapies do not have the same effect on all patients. This is particularly true in
the case of complex common diseases such as hypertension, diabetes and asthma, where a
diversity of pathogenetic factors may interact to produce the same disease, resulting in a
large degree of heterogeneity in the response to medical therapy. For this reason, the ability
to differentiate between different disease endotypes is of increasing importance to clinical
medicine.
In the case of asthma, initial studies have hinted at the presence of multiple disease
endotypes with different clinical characteristics. Additional studies have identified novel
genetic risk factors and differences in gene expression among asthmatic patients with different
disease endotypes. Despite the presence of large-scale clinical and molecular datasets from
asthmatic patients, limited efforts have been made to integrate these different formats to
develop a systems-level understanding of disease mechanism.
In this thesis, we develop a computational framework for addressing the problem of dis-
ease heterogeneity by integrating data from multiple sources, including the genome, phenome
and transcriptome in order to define clinically-relevant disease subtypes, and we demonstrate
its application in a cohort of asthmatic children. First we perform a cluster analysis of clin-
ical phenotypic data and detect the presence of multiple disease endotypes in a cohort of
children with mild-to-moderate asthma. We evaluate the clinical significance of these endo-
types by demonstrating their longtudinal stability and association with differential response
iv
to pharmacotherapy. Next, we develop a transcriptional network from the gene expression
profiles of these patients and identify the relationship between discrete patterns of expres-
sion and asthma endotypes. Finally, we combine longitudinally-derived clinical phenotypes
with genetic data to uncover novel genetic associations corresponding to changes in gene
expression and the expression of longitudinal clinical traits.
Keywords: computational biology, genomics, bioinformatics, machine learning, cluster anal-
ysis, genome-wide association study, gene expression profiling, disease endotypes, child-
hood asthma.
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1.0 INTRODUCTION
1.1 MOTIVATION
The rapid development of computational methods in the field of statistical machine learn-
ing has provided us with the ability to recognize the distinctive patterns inherent in large
electronic datasets, with applicability to fields as diverse as high finance, text mining and
biomedicine. However, the complexity of biological systems, and in particular the human
body, has made it difficult to link disease patterns to systems-level pathogenesis until very
recently. There have been several high-profile developments in both computational meth-
ods and biomedical applications that have led to the unprecedented opportunity to leverage
massive amounts of electronic medical data for widespread clinical use. For example, the
electronic medical record (EMR) makes it possible to perform large-scale data mining of
patient clinical characteristics. Similarly, the development of high-throughput technologies
to assay the human genome and transcriptome through next generation sequencing and
oligonucleotide microarrays provide a wealth of genetic and genomic data. Co-incident with
these biomedical advances has been development of powerful data-mining algorithms, made
possible due to the increased computational ability of modern computers. The integration
of these algorithms with the vast array of biomedical data creates the ability to develop de-
tailed clinical and molecular profiles for individual patients that could be accessed through
the EMR.
One application for advanced data-mining techniques has been in disease phenotyping,
where cluster analysis has recently become popular [169] in a model-free setting [136]. Clus-
tering techniques were initially described as an application for disease diagnosis over 20 years
ago [50], however such methods were not successfully applied to large clinical datasets until
1
recent advances in both computing power and algorithmic efficiency made these methods
more scaleable, and their use more widely applicable. Eisen and colleagues were the first to
use clustering as a method of disease phenotyping [46]. Many subsequent papers have used
a similar approach to disease phenotyping, most notably for identifying asthma endopheno-
types [60, 118, 48], and all have been primarily descriptive in nature, using clustering as a
form of exploratory data analysis. The widespread adoption of these methods in the clinical
setting has been limited for several reasons, including the problems of quality control and
cluster validation, which make it difficult to move beyond pattern recognition toward using
the results of cluster analysis for risk-stratification and clinical decision-making [85].
An additional application for machine learning methods is relating genetic associations to
disease phenotypes. In recent years, much progress has been made toward understanding the
genetic underpinnings of complex diseases, such as asthma. For asthma, studies of disease
concordance among twins suggesting that asthma is a highly heritable condition [43, 73, 35,
163, 175, 42, 36, 126, 127, 99, 154]. This observation has led to a large-scale interrogation of
the human genome, resulting in the discovery of novel asthma-related genes, replicated in
multiple populations [143,69,47,71,117,147,63]. Yet, despite the preponderance of evidence
for the heritability of asthma, the previous genome-wide association studies (GWAS) have
determined only a small fraction of the total estimated heritability. A major issue leading
to this missing heritability is related to the fact that asthma is an enormously dynamic
disease, often with inter-individual differences manifesting as changes in severity measures
over time. Genetics studies that evaluate for associations at a single point in time are
underpowered to capture genetic effects that contribute to a disease trajectory, and not
simply a quantitative trait measurement at a specific point in time. The natural history
of asthma has an enormous amount of variability, and different individuals have different
clinical trajectories. Future efforts to identify associations with significant effects will be
more successful if we can incorporate dynamic changes in phenotypic traits into GWAS
analysis. Further, although asthma GWAS have discovered many novel associations, they
have not done much to explain or reveal the mechanisms behind this complex disease.
The integration of multiple large-scale datasets is another application for machine learn-
ing in biomedicine. There have been several early efforts to integrate transcriptional data,
2
obtained from microarray analysis with genetic association analysis to determine the genes
associated with changes in gene expression. One advantage to this approach is that it uti-
lizes intermediate phenotypes, and by integrating molecular data into association analyses,
brings us closer to discovering the genetic underpinnings of disease mechanisms. Several
studies have utilized this approach to better understand the disease mechanisms behind
asthma. Raby and colleagues integrated gene expression profiles from CD4+ T lymphocytes
with genetic data to identify several novel genetic determinants of gene expression levels
in asthmatic subjects [119]. Hao and colleagues performed large-scale genotyping and gene
expression profiling on a cohort of over 1,000 subjects and identified several novel genetic
variants significantly associated with changes in the expression of multiple asthma-related
gene transcripts [62]. In the same analysis, Hao et. al., integrated the gene expression with
cis-acting eSNPs to create a Bayesian network that allowed them to identify several genes
that were“key drivers” behind the molecular mechanisms involved in asthma. The utilization
of novel machine learning methods to further integrate multiple data types should provide
additional insights into asthma pathogenesis and novel therapeutic targets.
1.2 DISSERTATION OVERVIEW
The goal of this work is to create a computational framework for the integration of multiple
types of clinical and molecular data to better understand complex diseases. We apply this
framework to clinical, genetic and gene expression data from a cohort of children with mild-
moderate asthma to create predictive models for identifying disease endotypes with different
molecular mechanisms and responses to pharmacotherapy. A schematic of this framework is
depicted in Figure 1.1.
In Chapter 1, we provide background on the development cluster analysis as a computa-
tional tool. We describe its use in the biological and medical settings and its current use as a
tool for identifying clinical phenotypes. We describe the computational limitations of cluster
analysis as a clinical tool. In Chapter 2, we demonstrate an application of cluster analysis
to a childhood asthma dataset, with attention to limitations outlined earlier. We identify
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Figure 1.1: Graphical overview of integrative computational framework.
five distinct phenotypic clusters of asthmatics with discrete baseline clinical characteristics.
We validate our clusters by demonstrating their longitudinal consistency and demonstrating
marked between-cluster differences in long-term asthma control rates, pulmonary function
and response to anti-inflammatory asthma therapy, suggesting an potential role for cluster
analysis in the classification and clinical management of asthma.
In Chapter 3, we begin by describing biotechnological developments in gene expression
profiling, ending with an introduction to high-throughput assays. We highlight the statistical
challenges involved in the analysis of high-throughput datasets, and review the application of
this technology to disease phenotyping, with an emphasis on asthma. We end by introducing
recent computational advances in network analysis and potential applications to transcrip-
tional datasets. In Chapter 4, we demonstrate differential gene expression profiles among
asthmatic patients with different endotypes. Through a subsequent co-expression network
analysis, we identify a common motif within a module of highly correlated gene transcripts.
We also show capability of this module to predict the presence of atopy in an independent
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cohort of asthmatic patients.
In Chapter 5, we introduce the current state-of-the-art in genome wide association studies
(GWAS) and the statistical challenges present in such analyses. We describe computational
techniques such as time-series analysis and sparse regression for feature selection that may
be used to increase the power and improve the results and implications of GWAS. We end by
introducing a novel computational approach to GWAS, temporally-smoothed lasso (TESL)
used to leverage the time-dependencies present in longitudinal clinical data to increase the
power of GWAS. In Chapter 6, we apply TESL to a longitudinal asthma endotype and
demonstrate the presence of several novel and confirmatory asthma associations. We inte-
grate gene expression profiles obtained from GWAS subjects to show that several associations
correspond to novel expression quantitative trait loci (eQTLs).
The results of this work demonstrate the advantages of data integration in the biomedical
setting. Using the available data, we demonstrate the presence of multiple disease endotypes
among asthmatic children and show that different endotypes correspond to long-term differ-
ences in response to several well-known asthma medications. We also identify relationships
between these disease endotypes and molecular mechanisms through the integration of ge-
netic associations and transcriptional profiles.
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2.0 CLUSTER ANALYSIS AND ENDOTYPES
2.1 CLUSTER ANALYSIS
2.1.1 Definition
Clustering, or unsupervised learning, is a form of exploratory data analysis that involves
identifying subgroups within a set of objects. Clustering methods are useful for identifying
secondary patterns within a dataset. Mathematically, clustering involves iteratively optimiz-
ing an objective function such that the objects within a cluster subgroup are more similar
to each other than the objects outside of that cluster.
2.1.2 Methods of Clustering
There are multiple different methods of cluster analysis, with most variation occurring in the
formulation of the objective function. There are two general approaches to clustering. One
approach begins with each set of objects being assigned to its own cluster. As the algorithm
progresses, objects are iteratively assigned to larger and larger clusters. This method of
clustering is known as agglomerative, or “bottom up”. An alternative approach begins with
all objects being assigned to the same cluster. As the algorithm progresses, objects are
iteratively partitioned to smaller and smaller clusters. This method of clustering is known
as divisive, or “top down”.
2.1.2.1 Hierarchical Clustering Hierarchical clustering is characterized by a hierarchy
of subsets within a set of objects, and represents an agglomerative style of clustering. For
hierarchical clustering, there are two necessary metrics. The first is a distance metric, which
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is used to determine the degree of dissimilarity between two objects. There are multiple
distance metrics that may be used for clustering. One example is the Euclidean distance
metric, which is defined for two objects (a and b) as: ‖a − b‖2 =
√∑
i(ai − bi)2. Another
commonly used example, is the Manhattan distance metric: |a − b|1 =
∑
i |(ai − bi)|. The
second is a linkage metric, which is used to determine the distance between objects in different
clusters. For example, for average linkage clustering, at each iteration, the distance between
any two clusters, A and B is considered to be the average over all the distances between
all pairs of objects (a in A and b in B), or the mean distance between elements within
each cluster. Average linkage clustering is seen with the Unweighted Pair Group Method
with Arithmetic Mean (UPGMA) algorithm [148], popular in cluster gene expression data
generated from microarrays [37]. An alternative linkage metric is minimum, or single-linkage
clustering, in which the distance between two clusters A and B is determined by the distance
between the two objects in each cluster (a in A and b in B) that are closest to each other.
Limitations of hierarchical clustering include difficulty in interpreting the hierarchy, the
deterministic nature of the method, which prevents reevaluation after data points are grouped
into a node [5]. Furthermore, the tree structure can frequently lock in irrelevant features,
reflecting idiosyncrasies of the clustering rules, and early errors can lead to larger and larger
systematic clustering errors [159].
2.1.2.2 K-means Clustering K-means clustering is a divisive clustering method that
partitions a set of n objects into k clusters. In k-means clustering algorithms, k cluster
centers are initialized. Next each object is assigned to the nearest center based upon a
chosen distance metric. Finally the cluster centers are re-centered such that they become
the centroid of the set of points assigned to their respective cluster. These steps are iterated
until either the distance between the points in each cluster and the center is minimized,
or the maximal number of iterations has occurred. K-means optimizes the following error
function: F (µ,C) =
∑m
j=1 ‖µC(j) − xj‖2, where µC(j) is the center of cluster C and xj is
a datapoint (out of m datapoints) assigned to cluster C. K-means clustering is popular
due to its intuitive simplicity and speed. However, there are several drawbacks to this
method. First, the number of k clusters that are initialized must be determined in advance.
7
Because clustering frequently serves as a method for hypothesis generation, the optimal
number of clusters is often not known a priori. Second, because the initial location for
cluster centers is random, the results are not deterministic and may vary between different
clustering runs [122]. Third, k-means clustering is sensitive to outliers, and performs poorly
when clusters have a non-convex shape, or are non-linearly separable [84].
2.1.2.3 Spectral Clustering Spectral clustering is a relatively recent development in
the field of pattern recognition that has become popular due to its ability to outperform
alternative forms of clustering, such as k-means. In spectral clustering, data are encoded in
the form of an undirected graph G = (V,E), with data points encoded as vertices, vi for
i = 1...N where N is the total number of data points, and the relationship between data
points is encoded as edges, with weights wij encoding the strength of pairwise interaction
between two data points. The set of pairwise comparisons between data points forms an affin-
ity matrix, understood in spectral clustering as a weighted, undirected and fully-connected
graph. Because G is undirected, the weights are symmetric, wij = wji. The spectral ter-
minology comes from graph theory, and the spectral analysis of graphs. The calculation of
affinities between data points may vary depending on the structure of the data and the goals
of cluster analysis [110].
The details of clustering based upon the graph vary depending on the particular algorithm
used. One well-known spectral clustering algorithm continues by determining the degree
matrix, D [122]. D is a diagonal matrix, defined to be Dii =
∑n
i Gij where the i
th diagonal
element of D is the sum of the ith row of G. The next step is to calculate the Laplacian graph
L = D−G. The Laplacian is semi-definite, and may be decomposed into its eigenvalues and
eigenvectors, and thus encodes the connectedness of pairwise interactions between different
data points in the dataset. For example, if there are three dominant clusters in a set of data
points, the Laplacian will demonstrate three dominant eigenvectors. Next, the Laplacian is
normalized to scale the entries to a similar range Lˆ = D−1/2LD−1/2 and the eigenvectors are
extracted from the normalized Laplacian. A new matrix E is constructed that is composed
of the top k eigenvectors in the dataset, where k represents the putative number of clusters
present in the dataset. K-means clustering is then used to cluster the data points in E into
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k clusters.
The method of spectral clustering has many advantages over other clustering methods,
such as hierarchical and k-means clustering. One of the main advantages to spectral clus-
tering is that it does not make strong assumptions about the shapes of the clusters, which
is a major limitation of k-means clustering. In other words, the process of determining the
eigenvectors of the Laplacian matrix and clustering those eigenvectors allows the data points
to be assigned to the cluster to which they have the most connected relationship as opposed
to the most proximal cluster [122]. Thus, spectral clustering has the capacity to cluster many
different shapes and sizes of clusters that cannot be accurately cluster by other methods.
The main disadvantages of spectral clustering are related to the use of k-means clustering
and include sensitivity to initial parameter choices, such as the choice of k and the random
initialization of cluster centers for k-means clustering [38].
2.1.3 Defining the Optimal Number of Clusters
An open problem in cluster analysis is defining the optimum number of clusters present
in a dataset. Although cluster analysis is a pattern recognition tool that is of benefit in
learning more about the properties present in a dataset, most clustering method require
the user to define the number of clusters to be found within the dataset prior to beginning
any data analysis. This is problematic because early in the process of pattern recognition
and evaluation of a dataset, the optimum number of clusters is unknown, and little prior
knowledge is available. To address this problem, several techniques for determining the
optimal number of clusters in a dataset have recently been developed.
2.1.3.1 The Elbow Point One such method for determining the optimal number of
clusters involves evaluating the percentage of variance explained as a function of the number
of clusters. The number of clusters should be such that adding one more cluster does not lead
to measurable improvement in the percent of variance explained by the number of clusters.
In practice this method involves evaluating a plot of percent variance as a function of cluster
number. The point in the plot where the marginal improvement in percent variance begins
9
to levels off, or the so-called “elbow” of the plot should represent the point where the number
of clusters is optimal [95]. However, it can often be difficult to pinpoint exactly where this
“elbow” occurs.
2.1.3.2 The Silhouette Width The optimal number of cluster may also be estimated
by using the silhouette width. The silhouette width is a measure of how closely the data
points within a cluster are related to each other as opposed to how they are related to data
points in other clusters [141]. To calculate the silhouette width, for each data point i, we
let a(i) be the average dissimilarity of i with all other data within the same cluster. We
can interpret a(i) based on how well matched i is to the cluster to which it is assigned. We
then find the average dissimilarity of i using the data from another cluster. We repeat this
process for every cluster for which i is not a member and consider the lowest similarity to i to
be b(i). The cluster with the lowest similarity is considered to be the cluster that neighbors
i. Measure of similarity and dissimilarity are most commonly based upon an appropriately
chosen distance metric. After a(i) and b(i) have been found, the silhouette width can be
calculated by the following equation:
s(i) =
b(i)− a(i)
max{a(i), b(i)} (2.1)
Where s(i) values close to 1 imply more accurate clusters.
2.1.3.3 The Gap Statistic A newer method for calculating the optimal number of
clusters involves using the gap statistic. The way the gap statistic is calculated is by selecting
a range of values 1...N for the number of clusters present. Then, clustering is performed
on the original data points to find k clusters. A dispersion sum is calculated by summing
the distance between all data points and the mean of their assigned cluster. Next, a set
of reference data points similar in size to the original is created. This is typically done by
sampling from a rectangle formed from the original dataset’s principal components. Then
the dispersion sum of the reference set is calculated. Finally the gap statistic is calculated,
which is the log (mean dispersion of reference data points) - log (dispersion of original data
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points). This process is iterated over each range of values 1...N , and the optimal number of
clusters is determined from the value of k that leads to the largest gap statistic [165].
2.2 APPLICATIONS TO ASTHMA PHENOTYPING
In the past several decades, there has been a significant amount of progress in the treat-
ment of childhood asthma. The Global Initiative for Asthma (GINA) guidelines [10] and
multiple large-scale clinical trials [82,150,106], have helped to guide current evidence-based
treatments for this complex syndrome. The current stepwise therapeutic approach is de-
signed to maximize the overall level of asthma control and medication compliance while
minimizing treatment cost and adverse side effects. However, it is widely recognized that
clusters of asthmatic children not only respond differently to medications [158, 130], but
also exhibit markedly different disease trajectories, with many children outgrowing their
asthma by early adolescence, while others (often with more frequent exacerbations) show
disease progression [133, 93, 125, 144] or decreased lung function in adulthood [155]. The
lack of common or distinct histological features or reliable quantitative biomarkers suggests
that asthma may represent a collection of discrete disorders with some shared phenotypic
characteristics, but with distinct etiologies and natural histories. Such heterogeneity poses
significant clinical challenges, particularly in regards to long-term prognostication and treat-
ment decision-making.
Clustering methods have become popular in medicine as a way to explore the hetero-
geneity that is increasingly recognized to be present among patients with complex diseases.
For example, asthma has increasingly been recognized as a heterogeneous disease [173], and
several cluster analyses of patients with asthma have been performed to explore the presence
of disease-relevant subgroups within diverse cohorts of asthmatic patients. Numerous clas-
sification schemes based on specific presenting [140, 26, 27] or etiological [130, 120] features,
have been proposed. Though tailored treatment strategies are suggested for patients with
distinct forms (for example, the timing of long-acting bronchodilator use for the management
of exercise-induced bronchoconstriction), most classification schemes have limited utility in
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guiding management strategies or reliably predicting long-term morbidity. Recognition of
these limitations has motivated the development of multivariate models that consider many
patient characteristics simultaneously [120, 30, 49, 65]. More recently, a newer generation
of data mining procedures that leverage unsupervised machine learning approaches, have
been applied to large asthma cohorts, with early success in defining previously unrecognized
clusters of asthma patients [48,60,118]. However, these studies were limited by their lack of
prospective follow-up data, precluding assessment of the utility of these classification schemes
in informing treatment decision-making or disease prognostication.
2.3 LIMITATIONS OF PRIOR CLUSTER ANALYSES
There have been limitations to prior cluster analyses of asthmatic patients. One limitation
involved the use of naive clustering methods, such as k-means [60] and hierarchical cluster-
ing [118]. The limitations of these methods were described in the preceding sections, and we
sought to address this limitation by using spectral clustering in our approach. As described
above, spectral clustering has many advantages over hierarchical and k-means clustering,
including the ability to discern clusters of differing size and shape, which represents an ad-
vantage over k-means clustering. In addition, spectral clustering does not possess the same
vulnerability to outliers as hierarchical clustering.
In additional limitation of prior cluster analyses was the lack of a principled approached
for determining the optimal number of clusters. Moore and colleagues used hierarchical
clustering to partition a cohort of asthmatic patients into smaller subgroups [118]. However,
they did not specify a procedure for determining the cut points for different clusters in the
hierarchy. Haldar and colleagues used k-means clustering to cluster patients, but likewise did
not specify their procedure for optimizing the number of clusters. In the following analysis,
we sought to address this limitation by incorporating a formal procedure for optimizing the
cluster number into our workflow. We used the gap statistic over a range of cluster numbers
to determine the optimal number of clusters for our dataset [165].
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Although cluster analysis is useful for identifying patterns within a dataset, it does not
provide explanation of why such patterns might exist. Thus, the utility of phenotypic clusters
must be based upon the clinical relevance of observed clinical differences between clusters
to either risk-stratification or the more rational use of pharmacologic therapies. We address
this in our analysis by exploring the cross-sectional clinical differences between clusters,
which was done in earlier analyses. We also build upon earlier studies by exploring the
longitudinal consistency of clusters over time and differential response to medical therapy
between clusters.
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3.0 MULTIVARIATE ASTHMA ENDOTYPES
3.1 INTRODUCTION
We performed cluster analysis on a heterogeneous dataset of children with asthma in order
to explore the presence of distinct phenotypic cluster corresponding to clinically meaningful
differences between patients. In this analysis, we attempt to address many of the compu-
tational and clinical limitations of earlier cluster analyses performed on asthmatic children.
For this analysis, we evaluated participants in the Childhood Asthma Management Program
(CAMP) study [81, 82]. CAMP was a 4.5-year multi-center randomized, double-masked
clinical trial evaluating the long-term effects of inhaled budesonide vs. inhaled nedocromil
vs. placebo in 1,041 children with mild to moderate childhood asthma. In the primary
analysis, no differences in lung function improvement (the primary outcome) were observed
between treatment arms, though participants randomized to inhaled budesonide demon-
strated markedly improved long-term symptom control and reduced exacerbation rates as
compared to participants randomized to either inhaled nedocromil or placebo. In contrast
to prior phenotype clustering efforts [48, 60, 118], the availability of both extensive baseline
phenotypic data (collected following a 28-day screening period when participants were off all
asthma controller medications) and 48 months of prospective follow-up clinical trial data,
CAMP provides an opportunity to evaluate whether computational approaches can define
meaningful clusters with distinct clinical trajectories and/or treatment responses.
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3.2 METHODS
3.2.1 Study Population
The CAMP study design and primary outcomes have been described [81,82]. Subjects aged
5 to 12 years were deemed eligible for enrollment if they (i) had mild-to-moderate persistent
asthma, defined by the presence of symptoms, the use of an inhaled bronchodilator at least
twice weekly, or the use of daily medication for asthma; (ii) exhibited airway responsiveness
to methacholine; and (iii) they had no other clinically significant conditions. Participants
were randomized blindly to receive budesonide 200 µg twice daily (Pulmicort, AstraZeneca,
Westborough, MA; n = 311), nedocromil sodium 8 mg twice daily (Tilade, RhonePoulenc
Rorer, Collegeville, Pa.; n = 312), or matching placebo (n = 418). Subjects were evaluated
every four months, for a total of 48 months. Asthma exacerbations were treated by short
courses of oral prednisone. The addition of beclomethasone dipropionate (168 µg twice daily;
Vanceril, Schering-Plough, Kenilworth, N.J.) was allowed if asthma control was inadequate.
If control remained unsatisfactory, replacement or addition of medications was allowed.
3.2.2 Selection of Phenotypes
Phenotypic characteristics, including measurements of lung function, laboratory values,
asthma symptoms, and exacerbating factors were measured on each subject prior to and
at the time of randomization. From an initial list of 48 clinical variables (Table 3.1), we
selected a set of variables, representative of each childs degree of asthma burden, as inputs
to a clustering algorithm. Ten variables were excluded from consideration due to an excess
of missing data (greater than 10% of values missing). Due to the inherent strong correlation
between pre- and post- bronchodilator spirometric measures, we considered only one of the
two measurements (either pre- or post-bronchodilator) for FEV1, FVC, their ratio, and peak
flow. In addition, due to the subjective nature of many of the provocative variables, such as
animal dander worsens asthma, these variables were excluded from further analysis (Table
3.1). The resultant list for consideration included 18 variables. In contrast to prior studies,
potential asthma risk factors, such as gender, ethnicity and environmental exposure were
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purposely excluded from consideration for model building.
3.2.3 Preprocessing of Phenotypic Variables
Following variable selection, missing values were imputed using a k-nearest neighbor algo-
rithm from the pamr package of Bioconductor 2.51 [164]. Due to the fact that clustering
results may be affected by differences in scale among variables [33], vector normalization was
performed to scale each variable to a unit vector.
3.2.4 Cluster and Classification Analysis
We used spectral clustering [122], as implemented by the spec function of the kernlab pack-
age [89] of R 2.10.1, to partition the cohort into phenotypic clusters. In recognition that the
outcome of clustering methods is dependent on user-defined inputs, we used a data-driven,
iterative approach to define both the number of clinical variables to consider and the optimal
number of clusters to form. We considered a range of 1 to 10 for the number of clusters to
be constructed and, for each iteration, a set of initial cluster centers was generated from
a random set of rows in the data eigenvector matrix. We used the gap statistic [165] to
select the optimal number of clusters. We used the decision tree method [19, 138] to grow
a classification tree by binary recursive partitioning using the 18 variables from the above
clustering model to predict the phenotype cluster assignments.
3.2.5 Cluster Validation
3.2.5.1 Comparison to a Univariate Approach to Clustering We assessed the ef-
fect of using a single variable for cluster analysis on determining the final cluster assignments.
That is, Instead of using a multivariate model with 18 variables for cluster analysis, we used
each variable separately to perform the clustering. For the continuous variables, we specified
the formation of five clusters, to allow for comparison to the multivariate model. Using each
categorical variable independently led to the formation of two clusters. In order to compare
the univariate and multivariate approaches to clustering, we evaluated the ability of both
approaches to predict future exacerbations (ie. the time to first use of oral prednisone).
16
Medical History Reason for Exclusion
*Age of asthma onset included in model
Primary Caregiver’s assessment of asthma too subjective for model
*Atopic dermatitis included in model
*Positive allergy skin test included in model
*Prior hospitalizations for asthma included in model
*Emergency room visits for asthma included in model
*Hay fever included in model
Factors worsening Asthma Reason for Exclusion
House dust or Animals or Tobacco smoke < 10% missing values (cold air, aspirin),
or Emotional factors or Exercise or Certain foods remainder considered too subjective
or Respiratory infections or Dampness
or Changes in the weather or Cold air or Aspirin
Clinical Presentation Reason for Exclusion
Provoked by exercise These variables were considered
Provoked by allergy to be too subjective for use
Age at first symptoms in the clustering model
Symptom Burden Reason for Exclusion
Age when child began wheezing with shortness of breath > 10% missing values
Prior awakening from sleep due to cough or wheeze > 10% missing values
Awakening from sleep due in the past 6 months OR in past week > 10% missing values
Cough or wheeze during the day unrelated to exercise too subjective
Cough or wheeze during the day due to exercise > 10% missing values
Cough or phlegm with or without an upper respiratory infection > 10% missing values
Wheezing present on most days too subjective
Wheezing present with or without an upper respiratory infection too subjective
Wheezing present with shortness of breath too subjective
Two or more episodes of wheezing with shortness of breath > 10% missing values
Received a prescription medication for wheezing with shortness of breath > 10% missing values
Normal breathing between attacks of wheezing with shortness of breath > 10% missing values
Anthropomorphic Measurements Reason for Exclusion
*Body Mass Index All variables were included
* Waist / hip ratio in the model
Pulmonary Function Reason for Exclusion
*FEV1/ FVC All variables were
*post-BD FEV1 pre-BD FEV1/ included in the model
pre-BD FEV1 (BDR)
*Methacholine PC20 (natural log)
*Baseline peak expiratory flow rate
*Post-BD FVC as a percentage of
the predicted value (post-BD FVC % predicted)
*Pre-PD FEV1 as a percentage of
the predicted value (pre-BD FEV1 % predicted)
Peripheral blood measures Reason for Exclusion
*Total serum IgE level (log10) All variables were
*Absolute serum eosinophils (log10) included in the model
*Absolute serum lymphocyte count
*Absolute serum neutrophil count
Baseline clinical variables considered for cluster analysis. From an initial list of 48 variables shown in
the table, we selected 18 clinical variables (denoted by ∗) as inputs to the spectral clustering algorithm.
Table 3.1: Baseline clinical variables considered for cluster analysis.
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3.2.5.2 Comparison to an Alternative Clustering Algorithm In order to evaluate
the reproducibility of our cluster assignments we repeated the unsupervised analysis in the
CAMP cohort using a different clustering algorithm. As an alternative clustering method,
we selected hierarchical clustering because this was the method used in two well-known
studies of clustering in asthmatics patients, the Severe Asthma Research Program (SARP)
adult [118] and childhood [48] cohorts. These prior studies used hierarchical clustering with
Wards minimum distance as an agglomeration method, and we chose to use this clustering
method for validation of our clustering results. We used the hclust function of the stats
package in R 2.10.1 to generate five specified clusters and compared the composition of these
new clusters to our original cluster assignments. We also performed an outcomes analysis
with these new clusters and compared this to our original outcomes analysis.
3.3 RESULTS OF CLUSTER ANALYSIS
3.3.1 Phenotypes
Clinical phenotype data was available for all 1,041 participants. The baseline characteristics
assessed following a 28-day screening period off all anti-inflammatory asthma medications,
are presented in Table 3.2. As previously reported [81, 82], the demographic composition of
the CAMP cohort is consistent with that of childhood asthma in North America, including
a higher proportion of boys, early age of onset, and high prevalence of atopic features.
3.3.2 Cluster Analysis
Spectral clustering with 18 asthma-related baseline phenotypic characteristics observed many
high gap statistics; however, the maximum statistic was observed when considering five clus-
ters (Figure 3.1). Testing the model by leaving out one variable for each iteration confirmed
the importance of all 18 variables in the final model, as exclusion of any one resulted in
substantial subgroup fragmentation and inferior model performance (as measured by the
gap statistic, Table 3.3).
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Variable Count or Mean
Sex
Male (%) 621 (59.7)
Female (%) 420 (40.3)
Age (years) 8.94 ± 2.12
Self-reported race
White (%) 711 (68.3)
Black (%) 138 (13.3)
Hispanic (%) 98 (9.41)
Other (%) 94 (9.03)
Family history of asthma (%)
Yes 574 (55.1)
No 444 (42.7)
Missing 23 (2.21)
Family history of atopy (%) 724 (69.5)
History of tobacco smoke exposure (%) 439 (42.2)
Household income
< $30,000 242 (23.2)
≥ $30,000 758 (72.8)
Missing 41 (3.94)
Age of asthma onset, years 3.07 ± 2.44
Hospitalized for asthma (%) 320 (30.7)
ER visits for asthma, no./100 person-year 648 ± 62.2
History of atopic dermatitis (%) 298 (28.6)
History of hay fever (%) 557 (53.5)
History of positive skin test (%) 914 (87.8)
Pre-bronchodilator FEV1, L (range) 1.65 (0.42-3.31)
Pre-bronchodilator FEV1/FVC ratio (range) 80 (52-100)
FEV1 bronchodilator response, L (range) 0.10 (-3.77-2.59)
Total serum IgE levels, IU/L (range) 484 (0-5304)
Peripheral blood eosinophil count, log10 /L (range) 2.50 (0-3.72)
Waist to hip ratio 0.88 ± 0.061
Body Mass Index, kg/m2 18.2 ± 3.52
Table 3.2: Baseline features of 1,041 CAMP asthmatics.
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We also repeated the clustering analysis with consideration of subjects of self-reported
white ethnicity only (the largest ethnic group in the study), and found no differences in
cluster assignment (data not shown). Hence, our final model is optimal with respect to
the number of variables and clusters, and does not appear to be confounded by systematic
ethnicity-specific phenotypic differences.
Figure 3.2 presents a heat map of the clinical phenotypes grouped by cluster. Though
several variables segregate rather discretely by cluster grouping, all but five of the variables
included in the final model demonstrated significant differences in distribution across the
clusters (all p < 0.0001, denoted by * in Figure 3.2 and Table 3.4). Despite their prominence
in previously described asthma classification schemes, neither anthropomorphic measures
(BMI & waist:hip ratio) nor circulating leukocyte levels (neutrophil or lymphocyte levels)
were differentially distributed across the five clusters in this study.
3.3.3 Phenotypic characterization of the asthma clusters
Table 3.5 presents the distribution of asthma-related phenotypes across the observed clusters
and Table 3.5 provides a summary of the characteristic features of each cluster. The clusters
can be characterized best with respect to three groups of factors: (i) atopic burden (preva-
lence of atopic dermatitis, allergic rhinitis or skin test reactivity, total serum IgE and periph-
eral blood eosinophil levels); (ii) lung function and airway lability (pre-bronchodilator FEV1,
FEV1/FVC, bronchodilator response and methacholine airways hyper-responsiveness); and
(iii) baseline exacerbation rates (hospitalization and ED visit rates). Using these three groups
of variables, we constructed an Atopy-Obstruction-Exacerbation (AOE) classification scheme
by scoring each phenotype group as Low, Medium, or High. For clarity of subsequent dis-
cussion, although prospective long-term asthma control was not considered in the clustering
procedures (only baseline variables were considered), the cluster groups are also numbered in
ascending rank order of poor long-term asthma control (i.e. 1 = best control and 5 = worst,
as defined by need for oral steroid therapy during the ∼4.5 years of follow-up observation,
see below).
The largest group of patients (Cluster 1, 28.8% of cohort) represents the mildest cases,
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Higher gap statistic indicates greater between-cluster separation.
Figure 3.1: The gap statistic as a function of the number of clusters.
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Variable Range of Values Optimal number of clusters
for each variable with variable removed†
Age of onset (years) 0-12 10
Hospitalized for asthma 9
Missing 0
Yes 320
No 721
ER visits for asthma (number in past year) 0-12 3
History of atopic dermatitis 7
Missing 1
Yes 298
No 742
History of a positive skin test 10
Missing 0
Yes 914
No 127
FEV1 bronchodilator response (L)
Methacholine PC20 (natural log) -3.77-2.59 3
Peripheral blood eosinophils (log10) 0-3.72 6
Pre-bronchodilator FEV1/FVC (% predicted) 52-100 6
Pre-bronchodilator peak flow (L/min) 100-550 6
Waist to hip ratio 0.62-1.48 3
Total serum IgE levels (log10) 0.30-4.61 9
Body Mass Index (kg/m2) 12.7-34.3 3
Pre-bronchodilator FEV1 (% predicted) 44-148 4
Post-bronchodilator FVC (% predicted) 69-162 2
History of hay fever 10
Missing 5
Yes 557
No 479
Lymphocytes (%) 4-78 6
Neutrophils (%) 14-86 6
†Clustering robustness analysis. Each of the 18 variables used to perform the clustering analysis were
removed from the model one by one and the remaining 17 variables were used to perform the clustering.
Shown are the number of optimal clusters as determined by the gap statistic when a particular variable
was removed from the model.
Table 3.3: Range of Baseline Features of CAMP Asthmatics.
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Neutrophils
Lymphocytes
Post BD FVC % pred*
Log 10 eosinophils*
Waist/hip ratio
BMI
BD response*
Natural log PC20*
Pre BD peak flow
Pre BD FEV1/FVC*
Pre BD FEV1 %pred*
Log 10 IgE*
Positive skin test*
Hay fever history*
Atopic dermatitis*
ER visits*
Hospital history*
Age of onset*
1 2 3 4 5
The above heatmap depicts the differences among normalized clinical variables used for clustering and
the different cluster sub-groups. The cluster assignments are grouped along the horizontal axis and the
variables used to determine the cluster assignments appear along the vertical axis.
Figure 3.2: Heatmap of phenotypic trait distribution by cluster.
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Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P-value
(n=300) (n=202) (n=218) (n=225) (n=96)
AOE Classification LLL HLM HHM MHH HHH
Asthma history
Age of asthma onset (years) 3.52 ± 2.63 3.09 ± 2.40 3.66 ± 2.62 2.21 ± 1.89 2.27 ± 1.80 < 0.001
Total hospitalized for asthma 0 (0) 0 (0) 1 (0.46) 225 (100) 94 (97.9) < 0.001
(%)
ER visits for asthma 44.3 47.0 70.2 75.6 101 < 0.001
(visits / 100 person-years)
Atopic Features
History of atopic dermatitis 0 (0%) 202 (100%) 2 (0.1%) 0 (0%) 94 (97.9%) < 0.001
(%)
History of hay fever (%) 61 (20.3%) 132 (65.3%) 191 (87.6%) 119 (52.9%) 54 (56.3%) < 0.001
History of positive skin test 230 (76.7%) 185 (91.6%) 209 (95.9%) 198 (88%) 92 (95.8%) < 0.001
(%)
Total serum IgE levels (log10) 2.37 ± 0.70 2.72 ± 0.72 2.79 ± 0.58 2.64 ± 0.61 2.81 ± 0.63 < 0.001
Spirometry
Pre-bronchodilator FEV1 96.4 ± 12.7 97.7 ± 14.8 89.7 ± 13.9 91.4 ± 13.8 92.0 ± 16.1 < 0.001
(% predicted)
Pre-bronchodilator FEV1/FVC 81.8 ± 7.68 81.5 ± 7.59 77.6 ± 8.54 77.8 ± 8.24 78.6 ± 9.60 < 0.001
(% predicted)
Pre-bronchodilator peak flow 276.1 ± 67.3 274.3 ± 73.3 276.7 ± 69.1 276.4 ± 70.8 255.6 ± 73.3 0.12
Airway responsiveness
Methacholine PC20 (natural log) 0.71 ± 1.03 0.14 ± 1.11 -0.54 ± 1.00 0.038 ± 1.14 -0.23 ± 1.17 < 0.001
FEV1 bronchodilator response 0.077 ± 0.07 0.097 ± 0.08 0.12 ± 0.11 0.12 ± 0.11 0.16 ± 0.14 < 0.001
(L)
Anthropomorphic features
BMI 18.1 ± 3.46 18.6 ± 3.83 18.5 ± 3.66 17.8 ± 3.19 17.6 ± 3.38 0.07
Waist/hip ratio 0.882 ± 0.06 0.885 ± 0.07 0.881 ± 0.06 0.874 ± 0.05 0.877 ± 0.07 0.80
Peripheral blood counts
Eosinophils (log10) 2.35 ± 0.55 2.54 ± 0.53 2.57 ± 0.52 2.50 ± 0.49 2.71 ± 0.41 < 0.001
Lymphocytes (%) 42.1 ± 11.5 40.9 ± 9.82 41.1 ± 10.9 41.7 ± 10.5 40.8 ± 9.78 0.67
Neutrophils (%) 45.5 ± 12.2 44.5 ± 11.0 44.6 ± 11.5 44.7 ± 11.5 43.1 ± 11.0 0.62
Table 3.4: Distribution of Traits Across Phenotypic Clusters.
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with the lowest baseline exacerbation rates, lowest prevalence of atopic features, and pre-
served lung function (AOE classification LLL). The smallest cluster, Cluster 5 (9.3%), con-
sists of the most severe cases, with the highest baseline exacerbation rates, a very high atopic
burden, and reduced lung function (AOE group HHH). The three remaining clusters reflect
subsets with intermediate levels of severity and more heterogeneous clinical features. Clus-
ter 2 (19.3%) includes those subjects with high atopic burden but preserved lung function
(relative to the other groups) and intermediate airways hyperresponsiveness. This group has
an intermediate baseline exacerbation rate, with no reports of hospitalization (AOE group
HLM). Patients in Cluster 3 (20.9%) have high atopy burden, the most compromised lung
function, and extreme airways hyperresponsiveness, but have intermediate baseline exacer-
bation rates (AOE group HHM). In contrast, though patients in Cluster 4 (21.6%) are less
atopic to those of Cluster 2 (including lower rates of allergic rhinitis and skin test reactivity,
and lower serum IgE and peripheral blood eosinophil levels), and have reduced lung function
at levels similar to individuals in Cluster 3, they have very high exacerbation rates, partic-
ularly with respect to hospitalizations (AOE group MHH). It is clear that no one feature is
sufficient to characterize these groups.
3.3.4 Phenotypic clusters, long-term asthma control and response to specific
inhaled anti-inflammatory controller medications
To assess whether the derived cluster designations have clinical relevance regarding subse-
quent risk of exacerbations, we performed survival analysis of time to asthma exacerbation
over approximately 4.5 years follow-up. Consistent with the effective randomization of treat-
ment assignment, treatment group did not differ between clusters (p = 0.91, Table 3.6, Table
3.7), enabling unbiased assessment of the relationship between cluster grouping and long-
term asthma control (Figure 3.3). Kaplan-Meier analysis confirmed that cluster grouping
was strongly predictive of time to first course of oral prednisone (Figure 3.10a, Kaplan-
Meier log-rank p < 0.0001) and time to initiation of additional asthma controller therapies
(Figure 3.10b, p = 0.001). The most striking differences were observed within the first
12 months post-randomization, by which time the majority of subjects in Clusters 4 and 5
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Cluster 1: Relatively mild asthmatics with a low atopic burden (LLL)
• The largest subgroup of patients (28.8%)
• No history of atopic dermatitis, lowest prevalence of hay fever or skin prick test reactivity, lowest
IgE levels
• Preserved lung function(highest FEV1/FVC ratio)
• Lowest bronchodilator response, intermediate airway hyperresponsiveness.
• No prior hospitalization for asthma and the lowest reported prevalence of ED visits
• Lowest risk of poor long-term asthma control**
Cluster 2: Highly atopic asthmatics with preserved lung function (HLM)
• Universally report atopic dermatitis, high prevalence of allergic rhinitis and skin test reactivity
• Preserved lung function (highest FEV1)
• Intermediate bronchodilator response and airways hyper responsiveness
• No prior hospitalization, but intermediate rates of prior ED visits
• Low-intermediate risk of poor long-term asthma control**
Cluster 3: Highly atopic asthmatics with reduced lung function and severe airways
hyperresponsiveness (HHM)
• Rarely report atopic dermatitis (in contrast to HLM cluster),but highest prevalence of allergic
rhinitis and skin test reactivity
• Most reduced lung function (low FEV1/FVC ratio)
• High bronchodilator response and most severe airways hyper responsiveness
• Few prior hospitalizations, but intermediate rates of prior ED visits (similar to HLM cluster)
• Intermediate risk of poor long-term asthma control**
Cluster 4: Asthmatics with reduced lung function and high exacerbation rates, but
lower atopic burden (MHH)
• No history of atopic dermatitis, intermediate prevalence of hay fever (52.9%), lower IgE levels
• Most reduced lung function (low FEV1/FVC ratio, similar to HHH cluster)
• High bronchodilator response and most severe airways hyper responsiveness
• Most reports of prior hospitalization
• Intermediate risk of poor long-term asthma control**
Cluster 5: Asthmatics with most severe disease at baseline, high atopic burden, highest
exacerbation rates (HHH)
• Smallest subgroup of patients (9.3%)
• Nearly universal atopic dermatitis, highest prevalence of skin test reactivity, highest IgE levels,
highest eosinophilia, intermediate prevalence of allergic rhinitis
• Reduced lung function (low FEV1/FVC ratio) (similar to MHH cluster)
• Highest bronchodilator response and severe airways hyperresponsiveness
• Most reports of prior hospitalization and highest rate of ER visits
• Highest risk of poor long-term asthma control**
* Atopy-Obstruction-Exacerbation classification denoted in parenthesis.
** Poor long-term asthma control risk is defined from prospective survival analysis of time to first
course of oral prednisone. This variable was derived using the defined cluster groupings and was
therefore not considered in the spectral cluster analyses used to define the clusters.
Table 3.5: Summary of clinical characteristics of phenotypic clusters.
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(66% and 64%, respectively) had required at least one course of oral steroids, as compared
to only 56% and 54% of subjects in Clusters 3 and 2, and only 46% of patients in Cluster 1.
These established trends persisted for the remainder of the trial, with greater separation of
cluster groupings over time. At the end of the 4-year trial observation period, about a 3-fold
difference in the percentage of subjects not requiring oral prednisone was observed between
the two most extreme groups (32% in Cluster 1 vs. 11% in cluster 5, p < 0.0001). Simi-
lar relationships were noted for time to initiation of additional asthma controller therapies
(Figure 3.10b).
We next assessed whether treatment response to specific inhaled anti-inflammatory con-
troller medications differed by cluster group. As originally reported in the primary outcomes
assessment of the CAMP trial [82], use of inhaled budesonide, compared to placebo, sig-
nificantly reduced the number of asthma exacerbations Further, it was found that for the
entire cohort nedocromil did not significantly reduce exacerbation rates or additional con-
troller therapies compared to placebo. However, in a post hoc evaluation stratified by cluster
grouping, significant heterogeneity in treatment response rates to both medications is found
(Figure 3.4, Table 3.6, Table 3.7, 3.8, 3.9, 3.10): whereas subjects stratified to the three
more mild clusters demonstrated treatment response patterns similar to those reported in
the cohort as a whole, the therapeutic efficacy of nedocromil was similar to that of budes-
onide (as significantly greater than placebo) among subjects in the two most severe clusters
(Clusters 4 and 5) - those with the highest risk of exacerbation. Subjects in Cluster 4 those
with the lowest atopic burden, worst lung function, and high baseline exacerbation rates
demonstrated significant reductions in exacerbation rates when randomized to nedocromil
(1.7 fold reduction compared to placebo at 12 months, 1.6 fold reduction at 4 years) that was
similar to the reduction in exacerbation observed among those randomized to budesonide
(1.6 fold reduction compared to placebo at 12 months, 1.4 fold reduction at 4 years). In
this group, there was no difference in exacerbation reduction between those randomized to
nedocromil or budesonide (p = 0.96). Similar effects were noted in Cluster 5 (p = 0.22 for
difference between nedocromil and budesonide groups), though the magnitude of treatment
effect (compared to placebo) was substantially lower than for subjects in Cluster 4. For
subjects in Cluster 5- those with a high atopic burden, low lung function and the highest
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Figure 3.3: Survival analysis for phenotypic clusters.
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baseline exacerbations there was no decrease in exacerbation rate for subjects randomized
to either nedocromil (p = 0.56) or budesonide (p = 0.12).
3.3.5 Demographic, environmental, and familial determinants of phenotypic
clusters
We next assessed for associations between the observed clusters and known demographic,
environmental and familial features implicated in asthma pathogenesis that were not con-
sidered during clustering. Descriptions of demographic, environmental and familial clinical
variables across phenotypic clusters are presented in Table 3.11. Although trends for higher
proportions of non-Hispanic white subjects in the mildest group, and blacks in the most
severe groups were noted, these differences were not statistically significant. In contrast,
enlightening differences across clusters were observed for numerous environmental and fa-
milial factors. For example, though environmental tobacco smoke exposure was reported by
subjects in all five clusters, the prevalence was greatest among individuals in Clusters 4 and
5 those with the highest baseline exacerbation rates. However, among subjects in the less
severe clusters, a direct relationship between severity and smoke exposure was not observed:
those with the lowest childhood smoke exposure (Cluster 2, 30.2%) had higher baseline
exacerbation and greater airways hyperresponsiveness than subjects in Cluster 1 who had
significantly higher childhood smoke exposure (39.7%),and exacerbation rates, lung function,
and airways responsiveness were markedly different between Clusters 1 and 3 despite very
similar childhood smoke exposure rates (39.7% vs. 37.6%, respectively).
Similarly, though differences in aeroallergen exposure and in familial burden of both
asthma and atopy were observed across the five phenotypic clusters, obvious linear corre-
lations between risk factor exposure and severity of disease were not observed. Thus, with
the exception of age, where statistically significant differences were observed across cluster
groups, demographic variables including sex or socioeconomic indicators did not differ be-
tween clusters, suggesting that although environmental and genetic factors likely contribute
to the underlying pathobiological processes that determine cluster designation, none of these
variables are sole etiological determinants.
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Figure 3.4: Kaplan-Meier estimate by treatment group of the cumulative probability of
prednisone use during four years of follow-up, stratified by asthma cluster.
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Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P-value
(n=300) (n=202) (n=218) (n=225) (n=96)
AOE Classification LLL HLM HHM MHH HHH
Budesonide (n = 311, 29.9%)
2 months 0.06 ± 0.34 0.19 ± 0.61 0.18 ± 0.39 0.30 ± 0.90 0.19 ± 0.19 0.13
4 months 0.12 ± 0.22 0.30 ± 0.31 0.34 ± 0.41 0.54 ± 0.46 0.58 ± 0.36 0.003
8 months 0.39 ± 0.63 0.53 ± 0.52 0.71 ± 0.72 1.09 ± 0.82 0.92 ± 0.36 0.01
12 months 0.61 ± 0.67 0.72 ± 0.54 0.91 ± 0.58 1.44 ± 0.64 1.29 ± 0.31 0.004
16 months 0.78 ± 0.44 0.95 ± 0.65 1.21 ± 0.76 1.63 ± 0.42 2.22 ± 0.78 0.01
20 months 0.85 ± 0.38 1.15 ± 0.38 1.46 ± 0.58 1.87 ± 0.69 2.70 ± 0.44 0.01
24 months 1.07 ± 0.89 1.35 ± 0.72 1.57 ± 0.48 2.07 ± 0.44 3.04 ± 0.37 0.04
28 months 1.24 ± 0.46 1.47 ± 0.36 1.76 ± 0.50 2.39 ± 0.93 3.40 ± 0.38 0.04
32 months 1.39 ± 0.45 1.69 ± 0.58 1.96 ± 0.68 2.54 ± 0.47 3.63 ± 0.27 0.05
36 months 1.61 ± 0.62 1.98 ± 0.54 2.19 ± 0.48 2.85 ± 0.73 4.05 ± 0.42 0.03
40 months 1.75 ± 0.46 2.13 ± 0.39 2.33 ± 0.48 3.14 ± 0.74 4.52 ± 0.28 0.03
44 months 1.78 ± 0.31 2.23 ± 0.36 2.56 ± 0.49 3.03 ± 0.59 4.71 ± 0.20 0.02
48 months 1.94 ± 0.46 2.42 ± 0.63 2.86 ± 0.48 3.38 ± 0.52 5.00 ± 0.28 0.04
Nedocromil (n = 312, 30.0%)
2 months 0.21 ± 0.55 0.29 ± 0.65 0.22 ± 0.60 0.35 ± 0.65 0.54 ± 0.83 0.91
4 months 0.37 ± 0.43 0.55 ± 0.64 0.54 ± 0.56 0.61 ± 0.61 1.13 ± 1.18 0.06
8 months 1.03 ± 1.03 0.94 ± 0.52 1.12 ± 1.14 1.02 ± 0.68 1.59 ± 0.73 0.78
12 months 1.38 ± 0.70 1.26 ± 0.95 1.52 ± 0.78 1.46 ± 0.95 2.14 ± 0.99 0.66
16 months 1.71 ± 0.92 1.76 ± 1.11 1.94 ± 0.70 1.89 ± 0.80 2.78 ± 1.10 0.60
20 months 2.05 ± 0.51 2.10 ± 0.69 2.38 ± 0.79 2.15 ± 0.61 3.00 ± 0.52 0.55
24 months 2.33 ± 0.41 2.42 ± 0.69 2.92 ± 1.93 3.37 ± 0.60 3.50 ± 1.15 0.55
28 months 2.48 ± 0.47 2.74 ± 0.95 3.42 ± 2.07 2.53 ± 0.47 3.91 ± 0.83 0.62
32 months 2.65 ± 0.45 3.20 ± 0.94 3.74 ± 0.68 2.82 ± 0.65 4.29 ± 0.51 0.56
36 months 2.87 ± 0.60 3.27 ± 0.39 4.09 ± 0.65 3.29 ± 1.26 4.85 ± 0.58 0.28
40 months 3.14 ± 0.63 3.51 ± 0.40 4.29 ± 0.60 2.53 ± 0.63 5.15 ± 0.76 0.26
44 months 3.25 ± 0.35 3.78 ± 0.69 4.46 ± 0.67 3.80 ± 0.64 5.40 ± 0.64 0.22
48 months 3.56 ± 0.50 4.17 ± 0.67 4.67 ± 0.36 4.02 ± 0.82 5.42 ± 0.63 0.34
Placebo (n = 418, 40.1%)
2 months 0.30 ± 0.77 0.45 ± 0.86 0.37 ± 0.72 0.34 ± 0.71 0.41 ± 0.72 0.49
4 months 0.53 ± 0.52 0.84 ± 0.75 0.77 ± 0.65 0.83 ± 0.84 0.76 ± 0.69 0.16
8 months 1.07 ± 0.92 1.32 ± 0.81 1.21 ± 0.73 1.45 ± 0.96 1.61 ± 1.25 0.29
12 months 1.47 ± 0.93 1.80 ± 0.95 1.56 ± 0.66 2.12 ± 0.88 2.29 ± 1.47 0.04
16 months 1.97 ± 0.81 1.92 ± 0.50 1.71 ± 0.43 2.85 ± 0.97 2.77 ± 0.78 0.01
20 months 2.37 ± 1.03 2.30 ± 0.88 1.99 ± 0.58 3.65 ± 1.02 3.80 ± 1.72 <0.001
24 months 2.81 ± 0.95 2.84 ± 0.98 2.54 ± 1.06 4.23 ± 0.93 4.26 ± 0.78 <0.001
28 months 3.38 ± 2.47 3.14 ± 0.55 2.82 ± 0.51 4.75 ± 0.95 4.86 ± 0.92 <0.001
28 months 3.38 ± 2.47 3.14 ± 0.55 2.82 ± 0.51 4.75 ± 0.95 4.86 ± 0.92 <0.001
32 months 3.79 ± 0.96 3.42 ± 0.54 3.10 ± 0.70 5.30 ± 0.96 5.46 ± 0.92 <0.001
36 months 3.98 ± 0.51 4.09 ± 2.78 3.30 ± 0.43 6.01 ± 2.98 5.89 ± 0.70 <0.001
40 months 4.18 ± 0.49 4.34 ± 0.69 3.53 ± 0.53 6.32 ± 0.65 6.40 ± 0.71 <0.001
44 months 4.42 ± 0.63 4.64 ± 0.67 3.75 ± 0.55 6.65 ± 0.71 6.82 ± 0.78 <0.001
48 months 4.69 ± 0.52 4.72 ± 0.78 3.91 ± 0.46 6.89 ± 0.53 7.42 ± 0.86 <0.001
P-values
Budesonide vs. Nedocromil 0.0006 0.008 0.054 0.96 0.22
Budesonide vs. Placebo 0.0007 0.001 0.022 0.005 0.13
Nedocromil vs. Placebo 0.39 0.45 0.65 0.006 0.82
The cumulative number of subjects experiencing asthma exacerbations as demonstrated by the need for
oral prednisone therapy, at each study time point, stratified by treatment group. Shown are the mean
(±sd) cumulative number of prednisone bursts per person from the onset of the study period, p-values for
between-cluster differences in outcome (far right), and pairwise comparisons of within-cluster differences
in outcomes (bottom level).
Table 3.6: Number of prednisone bursts.
31
Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P-value
(n=300) (n=202) (n=218) (n=225) (n=96)
AOE Classification LLL HLM HHM MHH HHH
Budesonide (n = 311, 29.9%)
2 months 0.01 ± 0.11 0.04 ± 0.21 0.03 ± 0.18 0.00 ± 0.71 0.00 ± 0.72 0.32
4 months 0.01 ± 0.11 0.05 ± 0.21 0.03 ± 0.18 0.00 ± 0.84 0.04 ± 0.69 0.43
8 months 0.01 ± 0.12 0.06 ± 0.30 0.03 ± 0.18 0.06 ± 0.96 0.04 ± 1.25 0.66
12 months 0.03 ± 0.16 0.06 ± 0.39 0.07 ± 0.26 0.11 ± 0.88 0.13 ± 1.47 0.24
16 months 0.04 ± 0.20 0.06 ± 0.40 0.11 ± 0.31 0.13 ± 0.97 0.17 ± 0.78 0.21
20 months 0.05 ± 0.28 0.10 ± 0.43 0.13 ± 0.33 0.16 ± 1.02 0.17 ± 1.72 0.43
24 months 0.06 ± 0.29 0.10 ± 0.43 0.13 ± 0.33 0.18 ± 0.93 0.17 ± 0.78 0.38
28 months 0.10 ± 0.34 0.10 ± 0.43 0.15 ± 0.36 0.25 ± 0.95 0.26 ± 0.92 0.46
32 months 0.11 ± 0.36 0.10 ± 0.43 0.19 ± 0.44 0.26 ± 0.96 0.26 ± 0.92 0.43
36 months 0.18 ± 0.52 0.11 ± 0.45 0.21 ± 0.50 0.35 ± 2.98 0.30 ± 0.70 0.52
40 months 0.24 ± 0.64 0.11 ± 0.45 0.27 ± 0.63 0.51 ± 0.65 0.36 ± 0.71 0.27
44 months 0.25 ± 0.65 0.13 ± 0.47 0.31 ± 0.67 0.54 ± 0.71 0.38 ± 0.78 0.18
48 months 0.66 ± 0.92 0.37 ± 0.64 0.50 ± 0.71 0.82 ± 0.53 0.70 ± 0.86 0.27
Nedocromil (n = 312, 30.0%)
2 months 0.00 ± 0.00 0.02 ± 0.13 0.00 ± 0.00 0.02 ± 0.00 0.04 ± 0.00 0.33
4 months 0.00 ± 0.00 0.09 ± 0.35 0.02 ± 0.12 0.05 ± 0.00 0.17 ± 0.20 0.002
8 months 0.06 ± 0.23 0.19 ± 0.62 0.12 ± 0.38 0.11 ± 0.24 0.23 ± 0.20 0.20
12 months 0.13 ± 0.43 0.28 ± 0.94 0.14 ± 0.39 0.17 ± 0.36 0.36 ± 0.34 0.17
16 months 0.22 ± 0.60 0.41 ± 1.42 0.18 ± 0.46 0.26 ± 0.38 0.59 ± 0.48 0.15
20 months 0.30 ± 0.78 0.48 ± 1.58 0.23 ± 0.56 0.30 ± 0.55 0.68 ± 0.48 0.24
24 months 0.35 ± 0.93 0.52 ± 1.61 0.45 ± 0.94 0.40 ± 0.56 0.82 ± 0.48 0.27
28 months 0.38 ± 0.99 0.64 ± 1.80 0.62 ± 1.12 0.37 ± 0.67 0.86 ± 0.75 0.29
32 months 0.42 ± 1.11 0.69 ± 1.85 0.79 ± 1.36 0.49 ± 0.75 1.00 ± 0.75 0.19
36 months 0.48 ± 1.72 0.76 ± 1.95 0.86 ± 1.46 0.60 ± 0.88 1.15 ± 0.82 0.23
40 months 0.59 ± 1.44 0.84 ± 2.10 0.95 ± 1.59 0.69 ± 1.15 1.15 ± 1.00 0.29
44 months 0.65 ± 1.50 1.00 ± 2.45 1.05 ± 1.87 0.75 ± 1.13 1.15 ± 1.02 0.48
48 months 0.94 ± 1.66 1.27 ± 2.59 1.20 ± 1.79 1.00 ± 1.20 1.26 ± 1.22 0.92
Placebo (n = 418, 40.1%)
2 months 0.30 ± 0.77 0.45 ± 0.86 0.37 ± 0.72 0.34 ± 0.71 0.41 ± 0.72 0.49
4 months 0.53 ± 0.52 0.84 ± 0.75 0.77 ± 0.65 0.83 ± 0.84 0.76 ± 0.69 0.16
8 months 1.07 ± 0.92 1.32 ± 0.81 1.21 ± 0.73 1.45 ± 0.96 1.61 ± 1.25 0.29
12 months 1.47 ± 0.93 1.80 ± 0.95 1.56 ± 0.66 2.12 ± 0.88 2.29 ± 1.47 0.04
16 months 1.97 ± 0.81 1.92 ± 0.50 1.71 ± 0.43 2.85 ± 0.97 2.77 ± 0.78 0.01
20 months 2.37 ± 1.03 2.30 ± 0.88 1.99 ± 0.58 3.65 ± 1.02 3.80 ± 1.72 <0.001
24 months 2.81 ± 0.95 2.84 ± 0.98 2.54 ± 1.06 4.23 ± 0.93 4.26 ± 0.78 <0.001
28 months 3.38 ± 2.47 3.14 ± 0.55 2.82 ± 0.51 4.75 ± 0.95 4.86 ± 0.92 <0.001
28 months 3.38 ± 2.47 3.14 ± 0.55 2.82 ± 0.51 4.75 ± 0.95 4.86 ± 0.92 <0.001
32 months 3.79 ± 0.96 3.42 ± 0.54 3.10 ± 0.70 5.30 ± 0.96 5.46 ± 0.92 <0.001
36 months 3.98 ± 0.51 4.09 ± 2.78 3.30 ± 0.43 6.01 ± 2.98 5.89 ± 0.70 <0.001
40 months 4.18 ± 0.49 4.34 ± 0.69 3.53 ± 0.53 6.32 ± 0.65 6.40 ± 0.71 <0.001
44 months 4.42 ± 0.63 4.64 ± 0.67 3.75 ± 0.55 6.65 ± 0.71 6.82 ± 0.78 <0.001
48 months 4.69 ± 0.52 4.72 ± 0.78 3.91 ± 0.46 6.89 ± 0.53 7.42 ± 0.86 <0.001
P-values
Budesonide vs. Nedocromil 0.0006 0.008 0.054 0.96 0.22
Budesonide vs. Placebo 0.0007 0.001 0.022 0.005 0.13
Nedocromil vs. Placebo 0.39 0.45 0.65 0.006 0.82
The cumulative number of subjects experiencing asthma exacerbations as demonstrated by the need for
additional asthma controller therapy in the form of beclomethasone for each study time point strat-
ified by treatment group. Shown are mean values with standard deviations. Shown are p-values for
between-cluster differences in outcome (far right) and pairwise comparisons of within-cluster differences
in outcomes (bottom level). Mean (±sd) cumulative number of exacerbations per person from the onset
of the study period
Table 3.7: Need for additional asthma controller medications.
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Initiation of Initiation of additional
oral prednisone asthma controller therapies
Cluster
(reference is Cluster 1)
Cluster 2 0.03 0.50
Cluster 3 0.001 0.98
Cluster 4 < 0.0001 0.03
Cluster 5 < 0.0001 0.003
Treatment group
(reference is placebo)
Budesonide < 0.0001 < 0.0001
Nedocromil 0.32 0.53
Overall Interaction of
Cluster and Treatment Group 0.17 0.16
Age 0.08 0.35
Sex 0.50 0.53
Height 0.45 0.93
Cox proportional hazards models for risk of future asthma exacerbations using cluster assignment, age,
sex, height, and treatment group as predictor variables under an additive model. Cluster 1 was used
as the reference for cluster assignment. Shown are the p-values for the degree of risk each variable
contributes to the model.
Table 3.8: Summary of p-values for Cox proportional hazards modeling of risk of asthma
exacerbation.
Initiation of Budesonide Nedocromil Budesonide
oral prednisone (ref = placebo) (ref = placebo) (ref = nedocromil)
Drug < 0.001 0.28 < 0.001
Cluster 2 0.12 0.12 0.17
Cluster 3 0.03 0.03 0.06
Cluster 4 < 0.001 < 0.001 0.006
Cluster 5 < 0.001 < 0.001 < 0.001
Cox proportional hazards models for risk of future asthma exacerbations using cluster assignment and
treatment group as predictor variables under an additive model. Cluster 1 was used as the reference
group for cluster assignment. Shown are the p-values for the degree of risk each variable contributes to
the model.
Table 3.9: Summary of p-values for Cox proportional hazards modeling of risk of asthma
exacerbation.
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Initiation of Budesonide Nedocromil Budesonide
oral prednisone (ref = placebo) (ref = placebo) (ref = nedocromil)
Drug*Cluster 2 0.94 0.93 0.99
Drug*Cluster 3 0.93 0.87 0.97
Drug*Cluster 4 0.98 0.05 0.05
Drug*Cluster 5 0.92 0.60 0.50
Cox proportional hazards models for risk of future asthma exacerbations using cluster assignment and
treatment group as predictor variables under an interaction model. Cluster 1 was used as the reference
group for cluster assignment. Shown are the p-values for the interaction terms.
Table 3.10: Summary of p-values for Cox proportional hazards modeling of drug by cluster
interaction.
3.3.6 Decision-tree Algorithm for Efficient Patient Classification
To facilitate implementation of the AOE classification clinically without the need of machine
learning software, we screened combinations of the 18 cluster-building variables as candidates
to build a simple-to-use classifier. At least one variable from each of the three AOE classes
was considered in each model. The most accurate classifier (97% accuracy) included a his-
tory of previously being hospitalized for asthma (exacerbation), history of atopic dermatitis
(atopy), history of hay fever (atopy) and the natural log of the FEV1 PC20 (Figure 3.5.
Given that PC20 is not routinely obtained clinically in the pediatric setting, we assessed the
performance of the model by either removing PC20, or substituting PC20 with other variables
(including bronchodilator responsiveness). These maneuvers worsened model performance
(second best classification accuracy of 91.4%), with most misclassification occurring between
Clusters 1 and Cluster 3 (Figure 3.6), suggesting that airway hyperresponsiveness, is a key
factor in distinguishing cluster membership.
3.3.7 Cluster Validation
3.3.7.1 Longitudinal consistency in phenotype clusters With four years of prospec-
tive follow-up as part of the CAMP clinical trial, we were able to assess the consistency over
time in variable distribution across the five identified clusters. As demonstrated in Figure
3.7), quantitative measures of lung function and airways responsiveness were consistently
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Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 P-value
(n=300) (n=202) (n=218) (n=225) (n=96)
AOE Classification LLL HLM HHM MHH HHH
Sex 0.45
Male 173 (57.7%) 115 (56.9%) 130 (59.6%) 146 (64.9%) 57 (59.4%)
Female 127 (42.3%) 87 (43.1%) 88 (40.4%) 79 (35.1%) 39 (40.6%)
Age 0.003
Years, mean(± SD) 8.79 (±2.05) 8.83 (±2.12) 9.38 (±2.13) 9.03 (±2.08) 8.46 (±2.25)
Self-reported race 0.19
White 217 (72.3%) 137 (67.8%) 140 (64.2%) 150 (66.7%) 67 (69.8%)
Black 36 (12.0%) 27 (13.4%) 26 (11.9%) 35 (15.6%) 14 (14.6%)
Hispanic 27 (9.0%) 13 (6.4%) 31 (14.2%) 21 (9.3%) 6 (6.3%)
Other 20 (6.7%) 25 (12.4%) 21 (9.6%) 19 (8.4%) 9 (9.4%)
Annual Household Income 0.31
Less than $30,000 70 (23.3%) 40 (19.8%) 45 (20.6%) 66 (29.3%) 21 (21.9%)
Highest Household Education 0.13
Less than high school 1 (0.33%) 1 (0.50%) 2 (0.92%) 1 (0.44%) 0 (0.00%)
High school 5 (1.7%) 5 (2.5%) 4 (1.8%) 5 (2.2%) 4 (4.2%)
Higher education 125 (41.7%) 78 (38.6%) 87 (39.9%) 101 (44.9%) 48 (50.0%)
Family history
Asthma (Any) 154 (51.3%) 114 (56.4%) 137 (62.8%) 110 (48.9%) 59 (61.5%) 0.07
Asthma (Maternal) 64 (21.3%) 46 (22.8%) 70 (32.1%) 50 (22.2%) 32 (33.3%) 0.02
Asthma (Paternal) 40 (13.3%) 49 (24.3%) 58 (26.6%) 46 (20.4%) 15 (15.6%) 0.0009
Atopy (Any) 189 (63.0%) 158 (78.2%) 162 (74.3%) 139 (61.8%) 76 (79.2%) 0.0004
Atopy (Maternal) 114 (38.0%) 110 (54.5%) 112 (51.4%) 98 (43.6%) 53 (55.2%) 0.0009
Atopy (Paternal) 87 (29.0%) 90 (44.6%) 84 (38.5%) 73 (32.4%) 37 (38.5%) 0.05
Environmental Exposures
Tobacco smoke 119 (39.7%) 61 (30.2%) 82 (37.6%) 105 (46.7%) 46 (47.9%) 0.01
Dust mite 60 (20.0%) 36 (17.8%) 61 (28.0%) 44 (19.6%) 16 (16.7%) 0.30
Cockroach 1 (0.33%) 3 (1.49%) 1 (0.46%) 0 (0.00%) 0 (0.00%) 0.04
Randomized treatment arm 0.091
in CAMP clinical trial
Budesonide 86 (28.7%) 68 (33.7%) 60 (27.5%) 68 (30.2%) 29 (30.2%)
Nedocromil 94 (31.3%) 60 (29.7%) 66 (30.3%) 67 (29.8%) 25 (26.0%)
Placebo 120 (40.0%) 74 (36.6%) 92 (42.2%) 90 (40.0%) 42 (43.8%)
Table 3.11: Distribution of Non-classifying Features Across Phenotypic Clusters.
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A: Decision tree model for asthma classification. Nodes represent numbers of study subjects, branches
represent cut-points for clinical variables used in the model (shown at left). End-nodes are colored
corresponding to the cluster groupings in Figures 1 and 2. B: Performance of decision tree model in
classifying subjects into asthma clusters. C: Kaplan-Meier plot of the cumulative probability of a first
course of prednisone for the cluster assignments, as defined by the decision tree.
Figure 3.5: Asthma classification model.
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 Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 
Sensitivity 79.7 100 88.1 100 96.9 
Specificity 96.8 99.6 92.6 99.9 99.9 
PPV 90.9 98.5 75.9 99.6 98.9 
NPV 92.2 100 96.7 100 99.7 
No Yes 
104
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226 05 
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Yes No Yes No 
516 
263 253 
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Prior hospitalization for asthma 
Prior atopic dermatitis 	  
Cluster 1 
Cluster 2 
Prior hay fever 
Nodes represent numbers of study subjects, branches represent cut-points for clinical variables used in
the model (shown at left). Decisions trees was constructed without the PC20 variable.
Figure 3.6: Decision tree model for asthma classification.
separated across cluster groupings. These patterns persisted over the four-year period of
observation. For example, although methacholine PC20 is known to demonstrate marked
within-subject variability over time (for instance, the intra-class correlation of methacholine
PC20 during the CAMP clinical trial was 0.426, 95% confidence interval, 0.391 to 0.463 ),
the clear separation of methacholine PC20 across many of the clusters persisted over the
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four years of observation. A notable exception was pre-bronchodilator FEV1, which demon-
strated marked instability in cluster ranking, particularly towards the end of the observation
period. In contrast, post-bronchodilator FEV1 exhibited more consistent separation, similar
to other spirometric measures.
3.3.7.2 Comparison of univariate vs. multivariate cluster analysis We compared
our multivariate cluster analysis using 18 variables to a univariate approach, using each of
the 18 variables by itself. To evaluate the difference in the ability of each of these methods to
predict future exacerbations, as measured by the time to first use of prednisone, we performed
a survival analysis for each of the models. We found that the single variable with the best
predictive accuracy for future exacerbations was that of history of prior hospitalizations
for asthma exacerbations (Figures 3.8, 3.9). This variable was the only single variable to
outperform the multivariate phenotypic clusters in terms of its ability to predict future
exacerbations. However, despite this finding, we believe that the phenotypic clusters serve
as an improvement on the single variable approach in terms of their ability to capture the
total constellation of symptoms involved in asthma, for which exacerbation symptoms are
one of many important disease features, and atopic features and obstructive symptoms serve
as other important descriptors.
3.3.7.3 Reproducibility of cluster assignments using different clustering algo-
rithms Using hierarchical clustering, we were able to generate clusters quite similar in
composition to our original clusters in terms of AOE grouping (Table 3.12). To assess
whether the new cluster assignments also demonstrated longitudinal consistency similar to
the original clusters, we repeated our survival analysis of time to asthma exacerbation using
the four years of follow-up data generated as part of the CAMP clinical trial. For the survival
analysis, we found that the clusters generated using hierarchical clustering demonstrated a
similar natural history to our original clusters (Figure 3.10).
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Figure 3.7: Mean pulmonary function measurements by asthma cluster over four years of
follow up. P-values < 0.0001 calculated using linear mixed-effects models.
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Kaplan-Meier plots by cluster of the cumulative probability of a first course of prednisone during the
four-year follow-up period of the CAMP trial. Clusters were determined based upon a single clinical
variable, indicated at the top of each figure.
Figure 3.8: Survival analysis for single variable cluster analysis.
40
0 10 20 30 40
0.
0
0.
4
0.
8
Baseline peak flow
pvalue = 1.3e−05
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
cluster 1
cluster 2
cluster 3
cluster 4
cluster 5
0 10 20 30 40
0.
0
0.
4
0.
8
Waist/hip ratio
pvalue = 0.26
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
Log 10 IgE
pvalue = 2.6e−05
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
BMI
pvalue = 0.002
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
Baseline FEV1 % predicted
pvalue = 0.03
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
Post bd FVC % predicted
pvalue = 0.18
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
History of hay fever
pvalue = 0.19
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
Lymphocytes
pvalue = 0.73
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
0 10 20 30 40
0.
0
0.
4
0.
8
Neutrophils
pvalue = 0.57
Months of follow−up
N
o 
oc
cu
rre
nc
e 
of
 o
ut
co
m
e
Kaplan-Meier plots by cluster of the cumulative probability of a first course of prednisone during the
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Figure 3.9: Survival analysis for single variable cluster analysis.
New
1 2 3 4 5
Old 1 188 2 7 29 2
2 0 164 0 37 1
3 57 0 130 27 4
4 3 1 1 3 217
5 0 0 0 20 76
Table 3.12: Comparison of phenotypic clusters generated by hierarchical clustering (new
clusters) vs. spectral clustering (old clusters).
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Kaplan-Meier plots by cluster of the cumulative probability of a first course of prednisone A: or initiation
of additional asthma controller therapies (beclomethasone or other) B: during the four-year follow-up
period of the CAMP trial for hierarchical clusters.
Figure 3.10: Survival analysis for hierarchical clusters.
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3.4 DISCUSSION
The clinical heterogeneity of asthma has motivated the use of machine-learning algorithms
for the classification of patients using data-driven, unbiased criteria. While earlier work [60,
118,48] established the feasibility of this approach, many important questions remain unad-
dressed, including issues of reproducibility, generalizability and clinical relevance. Without
longitudinal follow-up, which was unavailable in prior reports, it is unclear whether the de-
fined clusters have clinical utility. It is in this context that the results of our phenotypic
clustering efforts and longitudinal analysis can be summarized.
First, we demonstrate the longitudinal consistency of our phenotypic clusters. When we
developed the clusters, we limited ourselves to the clinical data obtained during the baseline
assessment of CAMP participants. Next we evaluated for changes in cluster membership over
the 48 month study-period, and found remarkable consistency in phenotypic distributions
over time, particularly with regard to airway hyperresponsiveness, obstruction and exacer-
bation rates. These findings echo those of a recent longitudinal cluster analysis that found
membership in phenotypic clusters to be extremely stable over time [17]. An additional
finding of our study was that different inhaled anti-inflammatory medications appeared to
have no statistically significant effect on cluster membership over time, suggesting although
these medications may affect day-to-day symptoms, they have minimal effect on the natural
history of childhood asthma.
Second, we demonstrate the clinical utility of our phenotypic clusters. We found impor-
tant between-cluster differences in response to inhaled asthma therapies, with one cluster
(Cluster 4) showing decreased rates of exacerbations with both budesonide and nedocromil
therapy, while another cluster (Cluster 5) showed poor response with both budesonide and
nedocromil therapy. Our data suggest that although inhaled corticosteroids such as budes-
onide should serve as the primary treatment choice for asthma control in children with mild
to moderate asthma, there are several subgroups of patients, including those with the poor-
est level of baseline asthma control, who appear to respond to nedocromil at levels similar to
budesonide. Given safety concerns, particularly in children, regarding the long-term expo-
sure to inhaled glucocorticoid therapy, identification of phenotypic clusters that could benefit
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similarly from non-steroidal therapies would be of great value. While retrospective nature of
the current study and the small size of several of the clusters limits our ability to draw firm
clinical conclusions about the current results, our findings serve as the foundation for future
prospective clinical trials investigating personalized responses to inhaled anti-inflammatory
medications.
Finally, despite notable differences in the compositions of the patient populations, com-
putational algorithms employed, and the variables considered in generating the clusters, our
results show remarkable consistency with those obtained in the pediatric and adult SARP
populations, both with respect to the number of phenotypic clusters identified (5-6 clusters
in CAMP and SARP cohorts) and the patient characteristics of individual clusters. The
similarity of our phenotypic clusters to those of other cohorts provides further evidence for
the potential generalizability of clustering as a method of phenotyping asthmatic patients.
Observed differences in the degree of atopy and airway obstruction present in the pediatric
compared to the adult clusters lend further support to the hypothesis of etiological differences
between childhood and adult asthma.
Our study had several limitations. First, we evaluated only children, and reports have
shown that pediatric and adult asthma may represent two different disease states, with
different pathogenic mechanisms and natural histories [105]. For this reason, the clinical
implications of this cluster analysis may not be widely applicable to an adult asthmatic
population. Second, our study did not include severe childhood asthmatics. Because our
original population was ascertained for the purposes of a clinical trial, it included children
with mild-moderate persistent asthma, and specifically excluded those with more severe
asthma. Thus, there is a possibility that there is a severe childhood asthmatic phenotypic
that was missed with our analysis, although the strong similarities in observed clusters with
the childhood SARP study (which included a broader spectrum of disease severity) provides
reassurance that the results of our cluster analysis are more widely applicable. Third, the
conclusions that we can draw from the clinical outcomes of our clusters are limited due
to their small sample size. For example, the children in Cluster 5 had a limited response
to inhaled budesonide and nedocromil compared to placebo, suggesting that the children in
this cluster may have some resistance to corticosteroid therapy. However, because there were
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only 96 children in this cluster, we were underpowered to draw more clinically meaningful
conclusions from this particular analysis. It will be necessary to validate some of these
preliminary findings in future prospective studies to determine whether the children in this
cluster are truly steroid-resistant.
In conclusion, our results suggest support the use of computationally-inferred phenotypic
classifications of asthma as having clinical utility. These models define subsets of patients
with unique clinical attributes, discrete clinical trajectories, and variable responsiveness to
anti-asthma controller medications. Recognition of these clusters, and their clinical relevance
should motivate novel strategies in both the research and clinical settings. More refined phe-
notypic classification may better inform treatment decisions: as suggested by the results of
our treatment responsiveness analysis, cluster assignment identifies two subsets of patients
who respond similarly to both budesonide and nedocromil, providing clinicians with viable
treatment options for patients at risk for corticosteroid-related complications. The observed
between-cluster differences in environmental and genetic factors suggest that important eti-
ological differences underlie the configuration of different asthma subgroups. Future studies
that consider more homogenous subsets of patients should improve research precision in
characterizing the genetic and environmental etiologies. Thus, in addition to helping inform
clinical management, these more refined phenotypic classification schemes should help ac-
celerate research efforts in defining the molecular and environmental underpinnings of this
complex airways disease.
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4.0 GENE EXPRESSION AND ASTHMA ENDOTYPES
4.1 MEASUREMENT OF GENE EXPRESSION
In linking clinical phenotypes to mechanisms of disease, it is helpful to have biological as
well as clinical data to formulate hypotheses and make inferences. For human studies, this
involves obtaining either genetic material, proteins or other metabolites to explore associa-
tions between clinical symptoms and biomarkers. Gene transcripts, which may be stabilized
and isolated from biological specimens are useful because they represent the genes which
are actively being transcribed and are thus “turned on”. Although they do not provide
the amount of functional information provided by proteins and metabolites, they provide
a larger sense of the active processes involved in cellular metabolism than that provide by
exclusively studying the DNA genetic blueprint.
4.1.1 Molecular Biology Techniques
The ability to simultaneously profile large numbers of genes from patient samples is a rel-
atively recent development. Traditionally, levels of gene expression have been measured by
northern blotting. Northern blotting is a molecular biology technique that involves using
electrophoresis to separate RNA samples by size and detection with a hybridization probe
that is complementary to all or part of the target RNA sequence. After an RNA sample is
separated on an electrophoresis gel, capillary transfer is used to transfer the separated RNA
sequences to a blotting membrane [166]. The name for northern blotting is derived from
its relationship to Southern blotting, developed by Edwin Southern as an assay for DNA
sequences [151].
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Northern blotting continues to be in widespread use, however one of the limitations of
this approach is its relatively low throughput. Northern blotting is time-consuming, and
also unable to assay more than a few RNA sequences at any one time. In order to address
these limitations, Southern began researching techniques for multiplexing the assay of RNA
sequences. The results of his efforts led to the development of DNA microarray technology.
DNA Microarrays are used to measure the expression of large quantities of gene transcripts
simultaneously. Although the specifics vary depending on the particular microarray platform
used, DNA microarrays involve assembling a series of DNA probes onto a solid surface. Then
RNA is isolated from a biological specimen and is used to synthesized its complementary
cDNA sequence, which is more stable than RNA, which degrades rapidly after isolation. The
cDNA sequence is then hybridized to the DNA attached to the solid surface, and the hy-
bridization is detected and quantified using either fluorphore, or chemiluminescence-labeled
targets to determine the relative abundance of nucleic acid sequences that have hybridized
to the surface, (Figure 4.1) [152].
4.1.2 Adjustment for Multiple Testing
Along with the development of microarray technology, which has allowed for high through-
put gene expression profiling, has come the development of new statistical techniques to
analyze the vast quantities of data available. Although microarray results may be assessed
using traditional statistical techniques, such as the parametric ANOVA and Student’s t-test,
and non-parametric Kruskal-Wallis and Wilcoxon rank sum, adjustments must be made due
to the large number of statistical tests performed simultaneously when thousands of genes
are assayed at once. In statistical inference, when multiple statistical tests are performed
simultaneously, hypothesis tests that incorrectly reject the null hypothesis become increas-
ingly likely to occur. To address this issue, new statistical techniques have been developed
to prevent this occurrence, and allow significance levels for single and multiple comparisons
to be compared.
47
Reprinted from “DNA microarrays for comparison of gene expression profiles between diagnosis and
relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the
identification of potential diagnostic markers,” by F.J.T Staal et. al, 2003, Leukemia, 17, p. 1324-32.
Copyright 2003 by the Nature Publishing Group. Reprinted with permission.
Figure 4.1: Depiction of DNA microarray workflow.
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4.1.2.1 Control of the Familywise Error Rate One of the first techniques to address
the issue of multiple comparisons was the Bonferroni method [44]. This method involves
control of the familywise error rate (FWER). The FWER is the probability of making one or
more false discoveries, or type I errors when performing multiple hypothesis testing, that is,
FWER = Pr(V ≥ 1) where V is the number of false positive results. The goal of methods
like the Bonferroni method is to assure that the FWER is less than or equal some value, α,
such that the probability of making even one type I error within a family is controlled at
level α. In statistical inference, a family is understood to be the smallest set of items in an
analysis from which statistical inferences may be made.
Methods that control the FWER may control it in the weak sense, such as when control of
the FWER at level α is guaranteed only when all null hypotheses are true, or when m = m0,
where m is the total number of hypotheses and m0 is the number of null hypotheses. In this
case, the global null hypothesis is true, or may control the FWER in the strong sense, such
as when control of the FWER at levelα is guaranteed for any distribution of null hypotheses,
including the global null hypothesis.
For the Bonferroni method, let H1...Hm be a family of hypotheses and p1...pm be the
corresponding p-values resulting from significance testing, and let I0 be the subset of the
true null hypotheses, having m0 members. The FWER is the probability of rejecting at least
one of the members in I0. The Bonferroni correction demonstrates that rejecting all pi <
α
m
will control the FWER ≤ α, where m is the total number of hypotheses. The proof follows
directly from Boole’s inequality:
FWER = Pr
{⋃
i0
(pi ≤ α
m
)
}
≤
∑
i0
{
Pr(pi ≤ α
m
)
}
≤ m0 α
m
≤ mα
m
= α (4.1)
The Bonferroni method of correction is useful in situations where it is unsuitable to have
just one false positive value. However, in practice, this is often not the case. Furthermore,
this particular method of correction controls the rate of false positives at the expense of
increasing the number of false negative results.
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4.1.2.2 Control of the False Discovery Rate For the analysis of microarrays, control
of the familywise error rate is often too stringent, and results in an unacceptable level of false
negative results. In order to address this problem and increase the power of statistical analy-
ses, Benjamini and Hochberg developed a method to control the false discovery rate (FDR),
as opposed to the familywise error rate. This approach involves controlling the expected
proportion of false positives [12]. For the FDR method, Q is defined as the proportion of
false discoveries among the total discoveries (Q = V
R
), where V is the number of false positive
results, and R is the number of rejected null hypotheses, or discoveries. Assuming that S is
the number of true positive discoveries, the FDR is:
FDR = Qe = E[Q] = E
[
V
V + S
]
= E
[
V
R
]
(4.2)
Where V
R
is defined to be 0 when R = 0. Thus, the FDR may be controlled at a level
α, or q, where the q-value is equivalent to the p-value in the FDR setting. The q-value
of an individual hypothesis test is the minimum FDR at which the test may be considered
significant. For the analysis of microarray data, it is common to directly estimate q-values
as opposed to fixing the level at which to control the FDR [153].
For the Benjamini-Hochberg (BH) method to control the FDR at level α:
1. For a given α, we find the largest k such that P(k) ≤ kmα
2. Reject all H(i) for i = 1, ..., k
The BH method is valid when the m hypothesis tests are independent as well as situations
of dependence that satisfy the following inequality [13]:
E(Q) ≤ m0
m
α ≤ α (4.3)
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4.2 GENE EXPRESSION APPLICATIONS TO ASTHMA PHENOTYPING
Gene expression profiling and microarray technology have become popular in recent years
as an unbiased way to understanding relationships between disease states and the levels of
gene transcripts. This technology has been widely adopted in the study of asthma due to
its potential to uncover novel genes and pathways involved in disease pathogenesis. One of
the main applications of gene expression profiling to the study of asthma has been through
profiling gene transcripts in different cell types in order to understand the mechanisms of
asthma pathogenesis in different compartments.
Several early studies in asthmatic patients obtained bronchial biopsy specimens from
patients with asthma. One of the earliest gene expression profiling studies was one by
Dolganov and colleagues using real-time polymerase chain reaction (PCR) to quantify tran-
scripts [39]. In another study, Laprise and colleagues performed a microarray analysis on
bronchial biopsy specimens obtained from patients and compared levels of gene expression
between those with mild asthma and non-asthmatic controls [104]. They found differential
levels of gene expression among multiple genes, including some like nitric oxide synthase
2A (NOS2A), that had been previously implicated in asthma, and others, like arachidonate
15-lipoxygenase (ALOX15), not previously implicated in asthma pathogenesis. Other gene
expression profiling studies performed on bronchial biopsy specimens include a recent study
by Choy and colleagues that evaluated a large cohort of asthmatic and non-asthmatic sub-
jects [25], and an RNA sequencing study by Yick and colleagues that uncovered differential
expression of multiple novel and confirmatory asthma-related gene transcripts [186].
Gene expression profiling among asthmatic subjects has included multiple leukocyte
cell types, including polymorphonuclear leukocytes [59, 3, 156, 16, 145], neutrophils [6], ba-
sophils [187], alveolar macrophages [112], CD8+ T lymphocytes [167] and CD4+ T lympho-
cytes [61, 88, 78]. Other physiologic compartments that have been studied include airway
epithelial cells [177,178] and airway smooth muscle [157]. All of the aforementioned studies
describe both novel and confirmatory asthma-related changes in gene expression profiles, as
well as imply the clinical utility of gene expression profiles as biomarkers for asthma pheno-
types, particularly in situations where gene transcripts are assayed by non-invasive means,
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such as induced sputum [7].
In addition to demonstrating differential gene expression between patients with and with-
out asthma and with different asthma phenotypes, several studies have used classification
and clustering methods to identify predictive signatures for asthma phenotypes. For ex-
ample, Shin and colleagues used multiple logistic regression to optimize a gene expression
signature with the power to discriminate between asthmatic and non-asthmatic subjects
with high sensitivity and specificity [145]. Woodruff and colleagues performed an unsu-
pervised hierarchical cluster analysis of gene expression profiles of asthmatic patients and
evaluated for correlations between gene expression clusters and clinical characteristics [178].
Similarly, Baines et. al, performed hierarchical clustering on gene expression profiles from
induced sputum specimens of asthmatic patients and correlated several clusters with clinical
characteristics, such as the degree of airway obstruction present among study subjects [7].
However, all of the above studies stop short of validating their gene profiles in an independent
population, limiting their clinical utility.
4.3 LIMITATIONS OF PRIOR GENE EXPRESSION ANALYSIS
As described in the previous section, there have been a large number of studies evaluating
differential gene expression levels among asthmatic patients. However, there is limited infor-
mation with respect to the relationships between the gene transcripts. The gene expression
profiles of thousands of genes afford the unique opportunity to evaluate gene-gene interactions
using computational algorithms to “reverse-engineer” gene networks. Such networks could
be used to identify sets of gene transcripts with similar expression patterns, which could then
be used to explore the presence of common regulatory transcription factors (gene-sequence
interactions). Gene expression networks could also be used to explore common molecular
pathways among gene transcripts (gene-gene interactions) [53]. Prior studies have evaluated
gene clusters and signatures for enrichment in different molecular pathways, but none have
expressly studied the relationships between profiled transcripts and associations with asthma
phenotypes.
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4.4 GENE EXPRESSION NETWORKS
When studying gene expression profiles of large numbers of genes in patient samples, it is
useful to move beyond the detection differential expression levels between different patient
groups and toward the exploration of interactions between sets of genes. An advantage to
this approach is that it is more closely related to physiologic processes in which networks
of genes transcribe proteins that are active in metabolic pathways. The hypothesis is that
variation in gene expression leads to differences in these gene networks that is related to the
development of disease. Gene networks thus help to provide insight into the physiology of
cellular processes at the mRNA level. To this end, multiple methods have been developed
in an attempt to identify functionally related gene co-expression networks.
Gene networks display causal relationships between gene transcripts and are often rep-
resented by undirected graphs where the nodes of the graph are genes and the edges are
the causal relationships between genes. Gene networks can also be represented by adjacency
matrices. An adjacency matrix of a finite graph, G on n vertices is the nxn matrix where
the non-diagonal entry aij is the number of edges from vertex i to vertex j, and the diagonal
entry, ajj is the number of edges from vertex j to itself.
4.4.1 Early Methods of Inferring Gene Networks
Some of the earliest methods developed to identify gene networks were developed by the
work of Kauffman [91] and Thomas [162] on random Boolean gene networks. However, the
assumption that gene networks have a random topology has increasingly been questioned and
more recent assumptions are that gene networks possess scale-free [9] and small-world [170]
topologies, with a power law distribution for node connectivities.
Experimental mRNA levels obtained through microarray technology can provide a “snap-
shot” of the molecular state of cell populations at the transcript level, and are thus rich in
information that may be used to reverse engineer gene networks [18]. Understanding con-
nections between genes with similar expression patterns may help to reveal the structure
behind the process of transcriptional regulation. A relatively simple method for identify-
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ing potentially interacting genes has been termed the “guilt by association” method. In this
method, gene associations are explored through clustering algorithms [46] and principal com-
ponent analysis [68] and genes with similar expression patterns are grouped together. These
methods provide a corse-grained approximation of gene-gene interactions that may then be
followed up with more extensive analysis of the function of genes within the networks. These
methods work well in networks with a small number of connections, but the interpretation
becomes more ambiguous in the case of heavily connected networks.
4.4.2 Bayesian Networks
Other methods that have been used to develop gene networks include Bayesian belief net-
works [51,132,80]. Bayesian belief networks are probabilistic graphical models that represent
a set of random variables and their conditional dependencies in the form of a directed acyclic
graph (DAG), G [131]. In a Bayesian network graph, the nodes, X1, ...., Xn , represent vari-
ables, and the edges represent conditional dependencies between nodes. The component,
θ, describes a conditional distribution for each variable, given its parents in G. Thus, two
nodes that are not connected by an edge are considered to be conditionally independent.
Each node is associated with a probability function that takes as input a set of values from
the node’s parent variables and provides as output the probability of the variable represented
by the node.
The graph, G, encodes the Markov assumption, such that each variable Xi is independent
of its non-descendants, given its parents in G. Because G represents a series of conditional
independencies, any joint distribution that satisfies the Markov assumption may be decom-
posed into its product form. For example, consider a finite set χ = {X1, ...., Xn} of random
variables where each variable Xi can take on a value xi from the domain V al(Xi), then, we
may say:
P (X1, ...., Xn) =
n∏
i=1
P (Xi|PaG(Xi)), (4.4)
Where PaG(Xi) is the set of parents of Xi in G. To specify the joint distribution,
the product form of each of the conditional probabilities must also be specified, such that
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P (Xi|PaG(Xi)) for each variable Xi. The parameters that specify these distributions are
denoted by θ. Figure 4.2 depicts a sample Bayesian network structure and its conditional
independence relationships.
In the case of gene expression, the gene network can be used to compute the probabilities
of gene-gene interactions. The probability distribution is considered over all possible experi-
mental conditions, and the state of the system is described using random variables, where the
random variables represent the expression levels of individual genes. The complexity of these
models may be increased by adding additional attributes, such as experimental conditions,
temporal indicators, cellular locations, etc. Such models can be used to answer questions
related to the dependence of a particular gene on an experimental condition and the genes
that mediate direct and indirect dependencies.
Modeling Bayesian networks requires two stages: model selection (structure learning)
and parameter learning. Model selection involves learning a network structure and param-
eter learning involves estimating the probability values associated with each network node.
Bayesian networks may be learned from gene expression data by splitting the dataset into
a training set, D = x[1], ...., x[M ] of independent samples from an unknown distribution,
P (X), and estimating this distribution using G [132]. G may be learned by introducing a
statistically motivated scoring function to evaluate each network with respect to the training
data and searching for the optimal network according to this score [67]. One scoring func-
tion is based upon Bayesian reasoning scores candidate graphs by their posterior probability
given the data. From this network, it is possible to infer subnetworks of closely related genes
and to model perturbations in experimental conditions and effects on the genes within the
network.
Learning the Bayesian network structure may be reduced to an optimization problem
in the space of all DAGs. The number of such graphs is super exponential in the number
of variables and an exhaustive search of this space is thus intractable (NP-hard). For this
reason, in practice several heuristics must be employed, such as local optimization algorithms.
For example, for the sparse candidate algorithm, one identifies a small number of candidate
parents for each gene from simple correlations. The one restricts the search to networks
in which only the candidate parents of a variable can be its parents [51]. However, this
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This network demonstrates the following conditional independence relationships: I(A;B), I(C;D|A,B),
I(E;A,B,D|C), I(D;A,C,E|B), I(A;B,D), and the following joint distribution: P (A,B,C,D,E) =
P (A)P (B)P (C|A,B)P (D|B)P (E|C).
Figure 4.2: A simple Bayesian network.
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method may result in an overly restricted search space. An additional limitation of Bayesian
networks when applied to gene expression datasets is that the number of genes is often much
larger than the number of samples. The consequence of this is that it leads to a diffused
posterior probability over an extremely large model space that cannot possibly list all of the
plausible networks, given the data. To address this difficulty, smaller sets of features from
within the network may be sampled using Monte Carlo strategies to estimate the posterior
probability of those features, given the data [194,174,96].
4.4.3 Correlation Networks
An alternative method of inferring relationships between genes assayed using high-throughput
methods, such as microarrays is to infer the pair-wise correlations between genes [4]. The
pair-wise correlations between genes can be used to construct a gene relevance network,
where the network nodes correspond to gene expression, and the ith gene expression profile,
xi, is a vector whose components represent the gene expression values across m microar-
rays [76]. The co-expression similarity sij between genes i and j is defined as the absolute
value of the correlation coefficient between their expression profiles:
sij = |cor(xi, xj)| (4.5)
A thresholding procedure may be used to transform the co-expression similarity into a
measure of connection strength (adjacency) such that an unweighted network adjacency aij
between gene expression profiles is defined by hard thresholding the co-expression similarity
sij as follows:
aij =
1 if sij ≥ τ0 otherwise (4.6)
where τ is the hard threshold parameter. Two genes are related (aij = 1) if the absolute
correlation between their expression profiles exceeds the hard threshold τ . The advantage
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of this approach is that it leads to simple network concepts, but it may lead to the loss of
information when genes with correlations below τ are labeled as (aij = 0), even though there
is some weak correlation between them. To address this potential loss of information, it is
possible to define a weighted co-expression network that preserves the continuous nature of
the co-expression information. A weighted co-expression network may be defined as:
aij = s
β
ij (4.7)
with β ≥ 1. This soft threshold leads to a weighted gene co-expression network that em-
phasizes strong correlations while punishing weak correlations [189, 74]. A limitation of
this method is that it may lead to highly connected and dense networks of gene expression
values, which may be difficult to interpret. Therefore, with this method, after learning a
co-expression network it is often necessary to cluster the network into smaller more highly
correlated modules of genes. Genes within modules may be explored for functional relation-
ships and involvement in similar molecular pathways.
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5.0 USING GENE CO-EXPRESSION NETWORKS TO DEFINE ASTHMA
ENDOTYPES
5.1 INTRODUCTION
An important implication of recent advances in our understanding of asthma phenotypic
clusters is that we may use these clusters to uncover associated differences in pathogenetic
mechanism, and thus have the potential to identify new therapeutic targets, with increased
treatment specificity as well as new molecular biomarkers for improved clinical detection.
Several studies have furthered our current understanding of the relationship between pheno-
typic clusters and molecular mechanism. Woodruff and colleagues profiled a selected subset
of gene expression levels in asthmatic subjects and found that differences in gene expression
corresponded to differences in multiple clinical measures of asthma severity, demonstrating
a link between clinical phenotype and molecular mechanism [178]. Baines and colleagues
subsequently found a correspondence between transcriptional profiles and different clinical
characteristics in an asthmatic population. However, the cross-sectional nature of these
studies limits the clinical applicability of the findings [7].
In the current analysis, our goal was to link differences in gene expression levels to
longitudinally stable clinical phenotypes with demonstrated differences in response to medical
therapy. In a prior analysis, we evaluated for the presence of phenotypic clusters in a cohort
of children with mild-moderate persistent asthma obtained from the Childhood Asthma
Management Program (CAMP) study [82]. Among these children, we identified 5 distinct
phenotypic clusters with different degrees of airflow obstruction, rates of exacerbation and
atopic characteristics. We further found that these clusters demonstrated both longitudinal
consistency over the 48 month study period and differences in response to medical therapy. In
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the current study we extend our earlier analysis through an exploration of differences in gene
expression between different phenotypic clusters, with the goals of identifying novel molecular
biomarkers corresponding to different phenotypes and further elucidating the differences in
molecular mechanism between subjects in different clusters [77]. We uncovered the presence
of distinct gene co-expression modules in CD4+ lymphocytes isolated from the peripheral
blood of a subset of CAMP participants. Gene expression levels within these modules were
associated with different phenotypic clusters and were highly predictive of multiple clinical
characteristics, such as levels of atopy and asthma control. We validated these results in
an independent population, and evaluated for the presence of shared transcription factor
binding sites among the genes of each module.
5.2 METHODS
5.2.1 Study Population
CD4+ lymphocytes were isolated from peripheral blood samples collected from 299 subjects
from four clinical centers (Baltimore, Boston, Denver, St. Louis) participating in the Child-
hood Asthma Management Program (CAMP) Continuation Study, part 2 (CAMPCS/2).
CAMP was a multi-center randomized, double-masked clinical trial of the long-term effects
of three inhaled treatments for mild to moderate childhood asthma, with 1041 subjects en-
rolled [81]. Two subsequent 4-year observational follow-up studies of CAMP participants,
CAMPCS/1 and CAMPCS/2 were carried out upon completion of the original CAMP study.
Blood samples and clinical data for the current study were obtained during a routine CAM-
PCS/2 clinical visit between May 1, 2004 and July 31, 2007. The study visit included
questionnaire assessments of asthma symptoms and medication use.
5.2.2 RNA Extraction and Microarray Preprocessing
We isolated CD4+ T cells from the collected mononuclear cell layer using anti-CD4+ mi-
crobeads by column separation (Miltenyi Biotec, Auburn, CA) [86, 193]. Total RNA was
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extracted using the RNeasy Mini Protocol (Qiagen, Gaithersburg, MD) [22,57,58]. Expres-
sion profiles were generated with the Illumina HumanRef8 v2 BeadChip arrays (Illumina, San
Diego, CA) according to protocol. Arrays were read using the Illumina BeadArray scanner
and analyzed using BeadStudio (version 3.1.7) without background correction. Raw expres-
sion intensities were processed using the lumi package [40] of Bioconductor with background
adjustment with Robust Multi-Array Average (RMA) convolution [83] and log2 transforma-
tion of each array. The combined samples were quantile normalized. The complete raw and
normalized microarray data are available through the GeneExpression Omnibus of the Na-
tional Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/, accesion
ID GSE22324).
5.2.3 Identification of differentially expressed genes
In order to classify gene expression levels from multiple phenotypic clusters into differential
expression patterns, we used an empirical Bayes hierarchical modeling approach to calcu-
late the posterior probability of each gene expression value fitting a particular pattern of
expression [121, 94, 188]. For example, for this analysis, we were interested in patterns of
differential expression of genes across different phenotypic clusters. We developed a set of
49 theoretical pattern assumptions (Table 5.1), such as the assumption of the null hypoth-
esis of no differential expression across clusters for a gene, or the assumption of differential
expression across all cluster for a gene, and then calculated the posterior probability of each
gene fitting a particular pattern of expression. We assigned genes to the gene pattern with
maximum posterior probability.
5.2.4 Identification of gene co-expression modules
To identify dense subnetworks of genes with highly correlated expression levels, we used
the gene transcripts to model a weighted co-expression network [102]. The advantage of the
weighted co-expression network is that it does not rely upon arbitrary thresholds to determine
the presence of a connection between two transcripts. Instead, the weighted network uses all
correlations to develop a soft threshold. For transcripts that were identified as differentially
61
Pattern Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5 Interpretation
number
1 1 1 1 1 1 null hypothesis (none different)
2 1 2 3 4 5 all different
3 2 1 1 1 1 cluster 1 different, others similar
4 1 2 1 1 1 cluster 2 different, others similar
5 1 1 2 1 1 cluster 3 different, others similar
6 1 1 1 2 1 cluster 4 different, others similar
7 1 1 1 1 2 cluster 5 different, others similar
8 2 2 1 1 1 cluster 1, 2 similar, others similar
9 2 1 2 1 1 cluster 1, 3 similar, others similar
10 2 1 1 2 1 cluster 1, 4 similar, others similar
11 2 1 1 1 2 cluster 1, 5 similar, others similar
12 1 2 2 1 1 cluster 2, 3 similar, others similar
13 1 2 1 2 1 cluster 2, 4 similar, others similar
14 1 2 1 1 2 cluster 2, 5 similar, others similar
15 1 1 2 2 1 cluster 3, 4 similar, others similar
16 1 1 2 1 2 cluster 3, 5 similar, others similar
17 1 1 1 2 2 cluster 4, 5 similar, others similar
18 1 2 3 1 1 cluster 1, 4, 5 similar, others different
19 1 1 2 3 1 cluster 1, 2, 5 similar, others different
20 1 1 1 2 3 cluster 1, 2, 3 similar, others different
21 2 3 1 1 1 cluster 3, 4, 5 similar, others different
22 2 2 3 1 1 cluster 1, 2, similar, cluster 4, 5 similar
23 2 2 1 3 1 cluster 1, 2, similar, cluster 3, 5 similar
24 2 2 1 1 3 cluster 1, 2, similar, cluster 3, 4 similar
25 2 3 2 1 1 cluster 1, 3, similar, cluster 4, 5 similar
26 2 1 2 3 1 cluster 1, 3, similar, cluster 2, 5 similar
27 2 1 2 1 3 cluster 1, 3, similar, cluster 2, 4 similar
28 2 1 1 2 3 cluster 1, 4, similar, cluster 2, 3 similar
29 2 3 1 2 1 cluster 2, 4, similar, cluster 3, 5 similar
30 2 1 3 2 1 cluster 2, 4, similar, cluster 2, 5 similar
31 2 1 1 3 2 cluster 1, 5, similar, cluster 2, 3 similar
32 2 1 3 1 2 cluster 1, 5, similar, cluster 2, 4 similar
33 2 3 1 1 2 cluster 1, 5, similar, cluster 3, 4 similar
34 1 1 2 3 4 cluster 1, 2, similar, others different
35 1 2 1 3 4 cluster 1, 3, similar, others different
36 1 2 3 1 4 cluster 1, 4 similar, others different
37 1 2 3 4 1 cluster 1, 5, similar, others different
38 2 1 1 3 4 cluster 2, 3, similar, others different
39 2 1 3 1 4 cluster 2, 4, similar, others different
40 2 1 3 4 1 cluster 2, 5, similar, others different
41 2 3 1 1 4 cluster 3, 4, similar, others different
42 2 3 1 4 1 cluster 3, 5, similar, others different
43 2 3 4 1 1 cluster 4, 5, similar, others different
44 1 1 2 1 3 cluster 1, 2, 4 similar, others different
45 1 2 1 3 1 cluster 1, 3, 5 similar, others different
46 1 2 1 1 3 cluster 1, 3, 4 similar, others different
47 2 1 3 1 1 cluster 2, 4, 5 similar, others different
48 2 1 1 3 1 cluster 2, 3, 5 similar, others different
49 2 1 1 1 3 cluster 2, 3, 4 similar, others different
Table 5.1: Description of Gene Pattern Interpretations.
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expressed (DE), we constructed an adjacency matrix. Each entry in the adjacency matrix
was determined by the absolute value of the Pearson’s correlation coefficient between two
gene transcripts (xi, xj), adjusted so that the overall network was scale-free. The pairwise
connection strength between different transcripts (xi, xj) was calculated by the adjacency
function aij = |cor(xi, xj)|β, using the estimated power parameter, β to form a weighted
co-expression network.
We developed a soft threshold by selecting the parameters leading to a scale-free net-
work. We used the top transcripts from this network in a topological overlap matrix (TOM)
calculation, and 1-TOM was used as a distance matrix for subsequent hierarchical clustering
to form highly correlated co-expression modules.
5.2.5 Identification of Shared Regulatory Regions within Gene Co-Expression
Modules
In order to identify regulatory motifs among the genes within highly correlated co-expression
modules, we obtained the genomic coordinates for each transcript within each module and the
corresponding promoter sequence by querying the UCSC Genome Bioinformatics [168] and
BioMart data resources [15]. We searched position frequency matrices (PFMs) corresponding
to transcription factor motif matches within each promoter sequence using data from publicly
available sources, including the Human Protein DNA Interactome (hPDI) database [184],
and JASPAR. [142] We next mapped the PFMs corresponding to each binding motif back to
our set of promoter sequences to obtain sequence matches to the binding motif among our
set of promoters. We used a multinomial model with a Dirichlet conjugate prior to calculate
a probability score for each promoter-motif match, and considered a match successful if the
minimum score was greater than 90%.
5.2.6 Gene Ontology Enrichment Analysis
We performed a Gene Ontology (GO) enrichment analysis on the differentially expressed
transcripts in each gene co-expression modules. For each gene co-expression module, we
calculated all enrichments in the specified ontologies (CC = cellular component, MF =
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molecular function, BP = biological process), and collected information about the terms
with highest enrichment. We calculated an enrichment p-value for each GO term identified
using a Fisher exact test to evaluate the number of co-expression module genes present in
a particular GO ontology compared to the total number of background genes in that GO
category. As background we used all genes present in all of the GO categories (in any of the
ontologies).
5.2.7 Validation in an Independent Cohort
To assess the generalizability of the association between the gene co-expression modules and
atopy, we evaluated whether the genes in the blue module could be used to predict atopic
status in an independent cohort (N = 88) of atopic (N = 72) and non-atopic (N = 16) subjects
with (N = 68) and without asthma (N = 20). We used a gene expression dataset that was
publicly available on the GEO website (GSE473) and has been previously described [116].
We used the genes present in the blue module to grow a binary recursive partitioning decision
tree to predict phenotype cluster assignments within our patient population [20,139].
5.3 RESULTS
5.3.1 Distribution of phenotypic traits
Clinical phenotype data was available for all 299 participants. The characteristics assessed
within one month of the time blood was obtained for microarray analysis are presented
in Table 5.2. The clinical characteristics presented in the table represent follow up data
obtained between 9-14 years after the onset of the original CAMP study. The mean age
of study subjects was 20.4 years of age, compared to 5-12 years in the original study. The
ethnic and gender distributions were similar to those of the original study (Table 5.2).
Several measures of atopic burden were obtained at the time of sample collection, in-
cluding serum IgE and eosinophil levels. As was observed at the onset of the original study,
the degree of atopy was highest in Clusters 2,3 and 5 and lowest in Cluster 1 and Cluster
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4. Similarly, the spirometric values show a similar distribution to that obtained at baseline,
with Cluster 4 and Cluster 5 showing the highest levels of airway obstruction.
The number of active smokers represented a minority of this cohort (11.4%), with the
highest percentage of smokers in Cluster 3 (16.3%) and the lowest percentage of smokers in
Cluster 4 (4.3%).
5.3.2 Gene Transcripts Demonstrate Atopic Patterns of Expression
In order to understand the relative contribution of different genes to the formation of the
asthma phenotypic clusters, we performed gene expression profiling of individuals from dif-
ferent phenotypic clusters to detect patterns of expression. For the set of phenotypic clusters,
gene expression levels could be sorted into 49 distinct theoretical patterns (Table 5.1).
For each transcript in each phenotypic cluster, we calculated the posterior probability for
each of the 49 patterns and assigned the transcript to the expression pattern with maximum
posterior probability (MPP). Differentially expressed (DE) transcripts were defined as those
with MPP greater than a specific threshold set to limit the false discovery rate (FDR) to
< 0.05 for each of the DE patterns (2-49 in the table). Using this approach, we found that
99.7 percent of the DE transcripts were confined to 2 of the 49 possible DE patterns.
The expression pattern containing the highest number differentially expressed transcripts
(22,119 of 22,184 total transcripts) was the null hypothesis expression pattern, or the pattern
of no difference in expression between the different phenotypic clusters. The expression
pattern containing the second highest number differentially expressed transcripts (501 of
22,184 total transcripts) was the pattern of similar expression between Clusters 1 and 4 and
between Clusters 2, 3 and 5. Our earlier analysis of the clinical data from the CAMP study
demonstrated that Cluster 1 and Cluster 4 had the lowest atopic burden of the phenotypic
clusters. That is, at the time of initial recruitment to the CAMP study, clusters 1 and 4
had the lowest levels of atopic dermatitis (Cluster 1 = Cluster 4 = 0%), the lowest history
of hay fever (Cluster 1 = 20.3%, Cluster 4 = 52.9%), the lowest history of a positive skin
test (Cluster 1 = 76.7%, Cluster 4 = 88%), and the lowest log10 total serum IgE levels
(Cluster 1 = 2.37, Cluster 4 = 2.64). Thus, a large number of differentially expressed genes
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Cluster 1 Cluster 2 Cluster 3 Cluster 4 Cluster 5
N=102 N=50 N=49 N=70 N=28
AOE Classification LLL HLM HHM MHH HHH
Demographics
Age (years) 20.1 ± 2.0 20.3 ± 2.2 21.0 ± 2.2 20.7 ± 2.1 19.9 ± 2.4
Male (%) 59 (57.8) 37 (74.0) 24 (49.0) 44 (62.9) 20 (71.4)
Female (%) 43 (42.2) 13 (26.0) 25 (51.0) 26 (37 .1) 8 (28.6)
White (%) 84 (82.4) 35 (70.0) 34 (69.4) 53 (75.7) 21 (75.0)
African American (%) 11 (10.8) 13 (26.0) 10 (20.4) 16 (22.9) 6 (21.4)
Hispanic (%) 7 (6.9) 2 (4.0) 5 (10.2) 1 (1.4) 1 (3.6)
Atopic Features
Serum IgE 2.33 ± 0.66 2.85 ± 0.54 2.53 ± 0.60 2.60 ± 0.54 2.69 ± 0.52
(log10)
Serum Eosinophils 2.17 ± 0.50 2.37 ± 0.46 2.42 ± 0.35 2.34 ± 0.32 2.44 ± 0.31
(log10)
Spirometry
Pre-bronchodilator FEV1 98.2 ± 13.2 98.5 ± 10.9 98.4 ± 11.3 94.1 ± 13.7 97.0 ± 11.1
(% predicted)
Pre-bronchodilator FVC1/FVC 78.5 ± 7.67 78.5 ± 7.89 78.6 ± 7.55 76.2 ± 7.57 75.3 ± 9.64
(% predicted)
Pre-bronchodilator peak flow 576.6 ± 144.5 634.0 ± 157.1 564.0 ± 147.0 579.8 ± 137.8 598.8 ± 162.7
Airway responsiveness
Methacholine PC20 1.09 ± 0.56 0.91 ± 0.53 0.75 ± 0.47 0.92 ± 0.52 0.96 ± 0.58
(natural log)
Environmental
Exposures
Tobacco Smoking (%)
Yes 14 (13.7) 7 (14.0) 8 (16.3) 3 (4.3) 2 (7.1)
No 76 (74.5) 38 (76.0) 34 (69.4) 60 (85.7) 21 (75.0)
Average cigarettes
smoked per day 1.3 ± 4.1 1.2 ± 3.7 1.9 ± 4.7 0.5 ± 2.8 0.5 ± 2.1
Table 5.2: Characteristics of Study Subjects.
66
demonstrated an expression pattern that was associated with the degree of atopic burden
present among study subjects at the time of enrollment in the CAMP study, suggesting
atopic status was the primary driver of the change in gene expression for these transcripts.
5.3.3 Atopic Patterns of Expression form Highly Correlated Co-Expression
Modules
We explored the relationship between the 501 genes associated with atopic status by de-
termining whether this set of genes could be clustered into tightly correlated co-expression
modules with similar function and regulatory mechanisms. We calculated the correlation
coefficient among all of the transcripts that were differentially expressed for the atopic pat-
tern. We next partitioned these transcripts into co-expression network modules using the
previously described method [102,92] because previous work has demonstrated such modules
to be related to biological function [21,54,55,75].
In order to construct our weighted co-expression network, we determined the appropri-
ate soft-thresholding power β to which co-expression similarity is raised to calculate adja-
cency [190] based on the criterion of approximate scale-free topology. We chose a set of
candidate powers and examined the scale independence and mean connectivity for different
power thresholds. The result is shown in Figure 5.1. We chose a power of 16, which was
the lowest power for which the scale-free topology fit index reached 0.90.
Next we calculated the adjacencies between transcripts, using the soft-thresholding power
of 16. To minimize the effects of noise and spurious associations, we transformed the adja-
cency matrix into a Topological Overlap Matrix (TOM), and calculated the corresponding
dissimilarity. We used hierarchical clustering to produce a hierarchical clustering tree den-
drogram of gene transcripts.
In the dendrogram, each leaf (short vertical line) corresponds to a specific transcript.
Branches of the dendrogram group together densely interconnected, highly co-expressed
genes. In order to identify network modules, shown qualitatively as branches of the den-
drogram, we needed to partition the branches of the dendrogram, which we did by using
the Dynamic Tree Cut algorithm [103]. A representation of the gene co-expression network
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The left panel shows the scale-free fit index (y-axis) as a function of the soft-thresholding power (x -axis).
The right panel shows the mean connectivity (degree, y-axis) as a function of the soft thresholding power
(x -axis).
Figure 5.1: Analysis of network topology for different soft-thresholding powers.
clustered into highly correlated modules within that network is shown in Figure 5.2. Cluster
analysis grouped the gene co-expression network into 3 modules, shown in blue, turquoise
and grey. The most notable module of highly correlated gene transcript is the blue module,
while the relationship between genes within the grey and turquoise modules are more diffuse.
5.3.4 Gene Co-expression Modules Have Similar Regulatory Domains
To explore the presence of a common regulatory molecule for the genes in each co-expression
module, we evaluated for common motifs in the promoter region of genes within each module.
For the blue module, we identified 10 binding motifs with matches to the promoter region
of genes within that module. We used the PWMs for each binding motif to find sequences
matches within the promoter region of module genes. We found two motifs located within
the Zinc finger protein 3 gene (ZNF3) with 373 and 308 matches to promoter sequences,
depicted in Figure 5.3. These two motifs were similar in composition and each had multiple
matches to the promoter regions of the 63 gene transcripts within the co-expression mod-
ule, suggesting the possibility that either ZNF3 or a related protein may be a dimeric or
68
Network heatmap plot, all genes
Higher levels of correlated expression are shown in red. The axes display the clustering map with a
color bar for each module. Within the network are several modules, with the blue module showing a
highly correlated cluster of gene transcripts. A small highly correlated cluster is also present within the
turquoise module.
Figure 5.2: Representation of the atopic gene co-expression network and its modules.
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multimeric transcription factor.
5.3.5 Enrichment Analysis of Module Genes
Among the gene transcripts represented in our atopic expression pattern, we identified 3
distinct co-expression modules. The module assignment is plotted under the gene dendro-
gram in Figure 5.4. In order to better characterize the function of the 501 genes associated
with atopic burden in these 3 co-expression modules, we performed an enrichment analysis
to determine whether the set of genes in each module was enriched in different biological
processes, molecular functions and cellular locations. We assessed the Gene Ontology (GO)
annotations for the genes present in each of the modules. Table 5.3 depicts each module and
the primary GO categories for which each one was enriched. The blue and grey modules
were enriched for multiple immunologic categories, and we performed further analysis on
these modules because we hypothesized that the functional categories suggested potential
mechanisms of asthma pathogenesis.
5.3.6 Differentially Expressed Genes are Associated with Different Clinical Out-
comes
To explore the clinical relevance of these gene co-expression modules, we used linear model
to detect associations between genes within each co-expression module and a range of clinical
outcomes. We found that for the blue co-expression module, there was a subset of genes
that were significantly associated with self-reported activity limitation. (see Table 5.4)
5.3.7 Gene Co-expression Modules are Predictive of Atopic Status
The atopic signature developed from the blue module of gene expression profiles in the CAMP
dataset was predictive of atopic status in an independent dataset (see Table 5.5, Figure 5.5).
Of the 63 genes present in the blue module, five select genes successfully classified all of
the atopic patients in an independent cohort with a sensitivity of 100%. The genes in the
atopic signature were highly enriched for multiple immunologic pathways (see Table 5.6).
Evaluation of the genes present within the blue module revealed that of the 63 genes present
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Figure 5.3: Sequence logo for the two motifs with the largest number of matches to module
promoter sequences.
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Module Size P-value Bonferroni Genes in Ontology GO Term Name
Correction Term
blue 62 2.2e-05 2.9e-01 21 CC nuclear part
blue 62 6.8e-05 9.1e-01 5 BP pattern recognition receptor signaling p
blue 62 7.2e-05 9.6e-01 4 BP TRIF-dependent toll-like receptor signal
blue 62 7.9e-05 1.0e+00 5 BP innate immune response-activating signal
blue 62 8.0e-05 1.0e+00 4 BP MyD88-independent toll-like receptor
blue 62 1.0e-04 1.0e+00 4 BP toll-like receptor 3 signaling pathway
blue 62 1.0e-04 1.0e+00 5 BP activation of innate immune response
blue 62 1.2e-04 1.0e+00 54 CC intracellular
blue 62 1.5e-04 1.0e+00 4 BP Toll signaling pathway
blue 62 1.8e-04 1.0e+00 6 BP immune response-regulating signaling
grey 22 2.4e-04 1.0e+00 2 BP response to gonadotropin stimulus
grey 22 3.4e-04 1.0e+00 2 MF tumor necrosis factor receptor binding
grey 22 5.3e-04 1.0e+00 2 BP defense response to Gram-positive bacteria
grey 22 5.6e-04 1.0e+00 2 BP response to activity
grey 22 5.8e-04 1.0e+00 9 BP phosphate-containing compound metabolic
grey 22 7.2e-04 1.0e+00 2 MF tumor necrosis factor receptor superfamily
grey 22 8.0e-04 1.0e+00 2 BP leukocyte cell-cell adhesion
grey 22 1.1e-03 1.0e+00 1 BP negative regulation of L-glutamate
grey 22 1.1e-03 1.0e+00 1 BP positive regulation of translational
grey 22 1.1e-03 1.0e+00 1 BP negative regulation of branching
turquoise 413 1.0e-16 1.3e-12 342 CC intracellular
turquoise 413 3.7e-15 5.0e-11 305 CC intracellular organelle
turquoise 413 7.6e-15 1.0e-10 285 CC intracellular membrane-bounded organelle
Table 5.3: GO Enrichment Analysis.
Name Symbol p-value BH adjusted p-value
phospholipase C β2 PLCB2 0.01 0.22
mannosidase, α, class 2B, member 1 MAN2B1 0.02 0.22
SH3KBP1 binding protein 1 SHKBP1 0.02 0.22
SWI/SNF related, matrix associated, SMARCC2 0.02 0.22
actin dependent regulator of chromatin,
subfamily c, member 2
chromosome 19 open reading frame 24 C19orf24 0.02 0.22
mediator complex subunit 25 MED25 0.03 0.22
adrenocortical dysplasia homolog (mouse) ACD 0.03 0.22
ubiquinol-cytochrome c reductase UQCRC1 0.03 0.22
core protein I
calcineurin binding protein 1 CABIN1 0.04 0.22
poly (ADP-ribose) polymerase family, PARP10 0.04 0.22
member 10
proline-serine-threonine phosphatase PSTPIP1 0.04 0.24
interacting protein 1
BH = Benjamini-Hochberg adjustment for multiple testing.
Table 5.4: Blue Module Genes Associated with Activity Limitation.
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Metric (%)
Sensitivity (%) 100
Specificity (%) 87.5
Positive Predictive Value 100
(PPV) (%)
Negative Predictive Value 87.5
(NPV) (%)
Table 5.5: Accuracy of Atopic Gene Signature in an Independent Population.
in the module, a greater proportion of genes were underrepresented (Table 5.7) by the atopic
clusters than overrepresented Table 5.8.
5.4 DISCUSSION
Our analysis of gene expression profiles obtained from CAMP participants 9-14 years from
the study onset was notable for several key findings. First, regarding our previous cluster
analysis, in which we detected 5 phenotypic clusters using the baseline clinical data from
study subjects, we found that even after 9-14 years there continued to be longitudinal consis-
tency in the clinical characteristics of subjects within different phenotypic clusters. Second,
subjects with a higher degree of atopic features demonstrated differential expression in a
subset of genes enriched for immunologic processes closely tied to asthma pathogenesis. A
subset of these differentially expressed genes formed an atopic signature that we used to
successfully determine atopic status from gene expression profiles obtained from an inde-
pendent population of asthmatic subjects. Third, from our co-expression module of atopic
genes, we were able to define several highly correlated subnetworks with similar expression
levels. Evaluation of a selected subnetwork revealed the presence of a common motif among
the promoter regions of genes within the network that corresponded to a binding site for a
zinc-finger transcription factor.
In an earlier cluster analysis we performed using clinical data from participants in the
CAMP study, we found that children could be characterized in terms of 5 distinct pheno-
74
|SRM < 6.78738
IDH3G < 7.37639
TRAT1 < 8.25116 PFKL < 7.18729
TAB1 < 5.36377
atopic
non-atopic atopic
atopic
atopic non-atopic
Figure 5.5: Decision Tree Classification Model for Atopic Status.
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Name Symbol Atopic expression GO Annotation
relative to non-atopic
spermidine synthase SRM down-regulated GO:0003824:catalytic activity
isocitrate dehydrogenase IDH3G down-regulated GO:0006099:tricarboxylic acid cycle
3 (NAD+) gamma GO:0004449:IDH (NAD+) activity
GO:0000287:magnesium ion binding
T cell receptor associated TRAT1 up-regulated GO:0006968:cellular defense response
transmembrane adaptor 1 GO:0007173:EGFR receptor signaling
GO:0038095:Fc-epsilon receptor
signaling pathway
GO:0008543:fibroblast growth factor
receptor signaling
GO:0008543:innate immune response
GO:0001920:negative regulation of
receptor recycling
GO:0051051:negative regulation of transport
GO:0048011:neurotrophin TRK receptor
signaling pathway
GO:0048015:phosphatidylinositol-
mediated signaling
GO:0050850:positive regulation of
calcium-mediated signaling
GO:0050862:positive regulation of T cell
receptor signaling pathway
phosphofructokinase, liver PFKL down-regulated
TGF-beta activated kinase 1/ TAB1 down-regulated GO:0000187:activation of MAPK activity
MAP3K7 binding protein 1 GO:0000185:activation of MAPKKK activity
GO:0038095:Fc-epsilon receptor
signaling pathway
GO:0003007:heart morphogenesis
GO:0007249:I-kappaB kinase/
NF-kappaB cascade
GO:0001701:in-utero embryonic development
GO:0045087: innate immune response
GO:0007254:JNK cascade
GO:0030324:lung development
GO:0002755:MyD88-dependent toll-like
receptor signaling pathway
GO:0002756:MyD88-independent toll-like
receptor signaling pathway
GO:0035872:nucleotide-binding domain,
leucine rich repeat containing
receptor signaling pathway
GO:0070423:nucleotide-binding oligomerization
domain containing signaling pathway
GO:0051092:positive regulation of
NF-kappaB transcription factor activity
GO:0051403:stress-activated MAPK cascade
GO:0034166:toll-like receptor 10
signaling pathway
GO:0034134:toll-like receptor 2
signaling pathway
GO:0034138:toll-like receptor 3
signaling pathway
Table 5.6: Gene Signature Predictive of Atopy.
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Name Symbol Fold Change p-value BH adjusted p-value
RAB4B, member RAS oncogene family RAB4B 0.89 0.002 0.04
ITGA5 integrin, alpha 5 ITGA5 0.87 0.003 0.04
(fibronectin receptor, alpha polypeptide)
ubiquinol-cytochrome c reductase core protein I UQCRC1 0.85 0.004 0.04
isocitrate dehydrogenase 3 (NAD+) gamma IDH3G 0.85 0.004 0.04
solute carrier family 22, member 18 SLC22A18 0.86 0.004 0.04
proline-serine-threonine PSTPIP1 0.84 0.005 0.04
phosphatase interacting protein 1
chromosome 19 open reading frame 24 C19orf24 0.87 0.006 0.04
flotillin 1 FLOT1 0.86 0.007 0.04
canopy 3 homolog (zebrafish) CNPY3 0.87 0.007 0.04
mediator complex subunit 25 MED25 0.88 0.007 0.04
unc-45 homolog A (C. elegans) UNC45A 0.85 0.008 0.04
DEAD (Asp-Glu-Ala-Asp) DDX41 0.85 0.01 0.04
box polypeptide 41
cytochrome b561 family, CYB561A3 0.87 0.01 0.04
member A3
microspherule protein 1 MCRS1 0.87 0.01 0.04
phenylalanyl-tRNA synthetase, FARSA 0.88 0.01 0.04
alpha subunit
interleukin 17 receptor A IL17RA 0.85 0.01 0.04
TGF-beta activated kinase 1/ TAB1 0.87 0.01 0.04
MAP3K7 binding protein 1
nudix (nucleoside diphosphate linked NUDT16L1 0.87 0.02 0.04
moiety X)-type motif 16-like 1
cleavage and polyadenylation CPSF3L 0.87 0.02 0.04
specific factor 3-like
exocyst complex component 3 EXOC3 0.89 0.02 0.04
UPF1 regulator of nonsense UPF1 0.86 0.02 0.04
transcripts homolog (yeast)
spermidine synthase SRM 0.86 0.02 0.04
ribosomal protein S6 kinase, RPS6KB2 0.88 0.02 0.04
70kDa, polypeptide 2
nuclear prelamin A recognition factor NARF 0.87 0.02 0.04
DENN/MADD domain containing 1C DENND1C 0.88 0.02 0.04
HECT domain containing E3 HECTD3 0.89 0.02 0.04
ubiquitin protein ligase 3
nuclear protein localization 4 NPLOC4 0.86 0.02 0.04
homolog (S. cerevisiae)
adrenocortical dysplasia homolog (mouse) ACD 0.89 0.02 0.04
mannosidase, alpha, class 2B, member 1 MAN2B1 0.84 0.02 0.04
ATPase type 13A1 ATP13A1 0.88 0.02 0.04
phospholipase C, beta 2 PLCB2 0.85 0.02 0.04
zinc finger and BTB domain containing 17 ZBTB17 0.89 0.02 0.044
solute carrier family 25 SLC25A1 0.88 0.026 0.044
(mitochondrial carrier; citrate transporter),
member 1
coiled-coil domain containing 124 CCDC124 0.89 0.027 0.045
coiled-coil domain containing 124 CCDC124 0.89 0.027 0.045
VPS9 domain containing 1 VPS9D1 0.89 0.027 0.045
zinc finger protein 3 ZNF3 0.88 0.03 0.047
zinc finger protein 692 ZNF692 0.88 0.033 0.048
zinc finger protein 692 ZNF692 0.89 0.033 0.048
BRCA1 associated protein-1 BAP1 0.89 0.035 0.049
(ubiquitin carboxy-terminal hydrolase)
phosphofructokinase, liver PFKL 0.87 0.036 0.049
A kinase (PRKA) anchor protein 8-like AKAP8L 0.88 0.037 0.049
SWI/SNF related, matrix associated, SMARCC2 0.86 0.037 0.049
actin dependent regulator of chromatin,
subfamily c, member 2
ATP-binding cassette, sub-family F (GCN20), ABCF3 0.88 0.038 0.049
member 3
BH = Benjamini-Hochberg adjustment for multiple testing.
Table 5.7: Blue Module Genes Under-expressed by Atopic Clusters.
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Name Symbol Fold Change p-value BH adjusted p-value
T cell receptor associated TRAT1 1.23 0.008 0.04
transmembrane adaptor 1
Mdm4 p53 binding protein MDM4 1.15 0.02 0.04
homolog (mouse)
MyoD family inhibitor domain containing MDFIC 1.20 0.02 0.04
ribosomal protein S6 kinase, RPS6KA3 1.14 0.029 0.047
90kDa, polypeptide 3
caspase 8, apoptosis-related CASP8 1.19 0.03 0.047
cysteine peptidase
myeloid cell leukemia sequence 1 MCL1 1.18 0.038 0.049
(BCL2-related)
BH = Benjamini-Hochberg adjustment for multiple testing.
Table 5.8: Blue Module Genes Over-expressed by Atopic Clusters.
typic clusters, which differed in terms of atopic burden, airway obstruction and rates of
exacerbation. In this analysis, we found that an average of 12 years after the original study,
participants continued to exhibit cluster-specific differences in several clinical characteris-
tics, including differences in atopic features, spirometry and airway responsiveness. This
is notable because at this time, in contrast to the physiologic differences, many of these
patients described relatively mild symptoms. Furthermore, this finding, from the largest
randomized, placebo-controlled clinical trial with extended follow-up for children with mild-
moderate asthma, [29] suggests that the decreased symptoms many childhood asthmatics
describe as they age does not correspond to disease remission. In fact, the original patho-
genetic mechanisms appear to persist into young adulthood, albeit with minimal subjective
symptoms.
Gene expression profiles from CD4+ T cells collected from the same set of patients further
confirm the persistence of physiologic differences between asthmatics assigned to different
clusters. A set of 501 out of 22,184 total genes assayed displayed an expression pattern that
correlated with atopic status, and a subset of these genes formed a signature that was highly
predictive of atopy in an independent population of mild-moderate asthmatics, a finding
that lends further credibility to the hypothesis that different phenotypic clusters correspond
to differences in the underlying pathobiological mechanisms of asthma, as well as validating
the biological relevance of our longitudinal phenotypic clusters.
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Within our set of atopic genes, we were able to distinguish 3 highly-correlated gene co-
expression modules, corresponding to differences in multiple gene ontologic process groups.
Within one of these co-expression modules, we identified a transcription-factor binding site
motif that was present in the promoter region of most of the genes within the co-expression
module. The transcription factor motif was complementary to a binding site located in the
protein encoded by the zinc-finger 3 gene (ZNF3), or a protein with a similar structure. Al-
though the ZNF3 gene has not previously been linked to asthma, other zinc-finger proteins
have been associated with modulation of Th2 cell differentiation [98] and secretion of the
IL-17 cytokine, [109] both of which have documented associations to asthma pathogenesis.
Furthermore, the family of zinc-finger proteins forms a large class of transcription factors
with the potential to serve as therapeutic targets. [56,179] This finding has potential impli-
cations for the future of asthma drug development pipelines, that could focus efforts toward
developing drugs to target transcription factors that modulate widespread changes in the
gene expression levels of genes within a co-expression modules.
Our study had several limitations. One limitation was that while we identified a predic-
tive biomarker signature for atopy, this particular population of patients was largely asymp-
tomatic, reducing its potential for immediate clinical use. The availability of longitudinal
gene expression data from prospective studies could help to elucidate temporal changes in
the expression of these genes and their role in the pathogenesis of childhood asthma. An
additional limitation is that although we were able to identify a transcription factor binding
site motif in the promoter region of multiple genes within a co-expression module, we have
no experimental evidence validating this finding. Further work is necessary to validate the
existence of this motif within the co-expression module and its binding affinity for the ZNF3
protein.
In summary, our findings lend further support to the hypothesis that asthma pheno-
typic clusters are associated with differences in the underlying molecular mechanisms of
asthma pathogenesis. This finding has implications for drug development and personalized
approaches to the treatment of this complex disease. Further work will be necessary to val-
idate these early findings and explore the mechanistic differences between different clusters.
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6.0 GENETIC ASSOCIATIONS AND ENDOTYPES
6.1 QUANTITATIVE TRAITS
Variability in disease endotypes is hypothesized to be the result of multiple factors that are
both genetic and environmental. To improve risk-stratification and refine treatment options,
it is useful to identify genetic variants associated with disease endotypes. Defining variants
associated with specific endotypes will allow us to screen patients at risk for specific disease
manifestations. Disease endotypes may be described by variety of clinical traits that are
both discrete (hospitalized vs. not-hospitalized) and continuous (body weight and blood
pressure). Continuous traits often show a wide range of variation across a population that
may be attributed to genetic factors. These traits are referred to as quantitative traits, and
the causal genetic variants are referred to as quantitative trait loci (QTLs). In order to
model the genetic contribution to quantitative traits, we often assume that the phenotypic
value, y is a simple summation of genetic and environmental factors:
y = m+G+ E (6.1)
where m is a constant, G denotes the effect of all genes contributing to the phenotype, and
E denotes the environmental effects [146]. Both E and G are assumed to have mean = 0,
so that m represents the average phenotypic value. We may also assume that both E and G
are uncorrelated, and that the variance of G is σ2G, and the variance of E is σ
2
E. The variance
of y is the sum of σ2G and σ
2
E. The heritability, h, is defined as the percentage of phenotypic
variation with a genetic origin and is defined as the ratio of
σ2G
σ2y
.
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If we consider a specific locus as bi-allelic, with alleles A and a, at any given locus, the
genotype is defined as either AA, Aa or aa. If we let xM denote the number of A alleles (0
or 1) inherited from the mother, and xF denote the number of A alleles (0 or 1) inherited
from the father, then we may state that x = xM + xF . Thus, the total number of A alleles
in a particular genotype may be either 0, 1 or 2. We may thus model a quantitative trait as
follows:
y = µ+ α(xM + xF ) + δ|xM + xF |+ e (6.2)
where e is a random variable with mean = 0. The µ term is the mean value of y when an
individual is an aa− homozygote. The mean level of y for an AA− homozygote is µ + 2a,
and the mean level of y for an Aa−heterozygote is µ+α+δ. If δ = 0, the locus is considered
to be additive, which means that each A allele adds to the average value of the phenotype,
y. If δ = α, the locus is considered to be dominant, and a single A allele produces the full
genetic effect on the phenotype, y. Conversely, if δ = −α, the locus is considered to be
recessive, and a single A allele produces no effect on the phenotype, y, while two A alleles
are necessary to produce a full effect.
The number of A alleles in an individual is x = xM +xF , with xM and xF being Bernoulli
random variables. If we assume that each allele is independent with the same probability p
of an A allele, then the distribution of x is binomial, such that:
Pr(x = 2) = p2, P r(x = 1) = 2p(1− p), P r(x = 0) = (1− p)2 (6.3)
where p is the frequency of A in the population. Thus, the mean value of x is 2p2 + 2p(1−
p) + 0 = 2p, and the mean value of the phenotype, y, is m = µ + 2pα + 2p(1 − p)δ. The
variable e is assumed to incorporate all other factors contributing to trait variability. We
may rewrite the value of the phenotype as:
y = m+ {α + (1− 2p)δ}x[(xM − p) + (xF − p)]− {2δ}x[(xM − p)(xF − p)] + e (6.4)
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where [(xM − p) + (xF − p)] and [(xM − p)(xF − p)] are uncorrelated because xM and xF are
independent. Thus, the variance of y is:
σ2y = σ
2
A + σ
2
D + σ
2
e (6.5)
where
σ2y = sp(1− p)[α + (1− 2p)δ]2, σ2D = 4p2(1− p)2δ2, σ2e = var(e) (6.6)
where σ2A is considered to be the additive variance, σ
2
D is the dominance variance and the
locus specific heritability, h2 is
σ2A+σ
2
D
σ2y
.
6.2 MAPPING QUANTITATIVE TRAIT LOCI
6.2.1 Early Methods
In practice, we consider the contribution of multiple potential loci to a particular phenotype.
To model the contribution of a genotype, g to a complex phenotype, y, we may consider a
small number of QTLs with genotypes g1, ..., gp, such that there are 2
p distinct genotypes.
In this case, the mean value for the phenotype, y is:
E(y|g) = µg1,...,gp (6.7)
and the variance for y is:
var(y|g) = σ2g1,...,gp (6.8)
If we assume additivity:
µg1,...,gp = µ+
p∑
j=1
∆jgj (6.9)
where (gj = 1 or 0) We also assume a constant variance, σ
2
g ≡ σ2 and normally distributed
residual variation, y|g ∼ N(µg, σ2). Under this model, the simplest method of detecting ge-
netic associations to complex traits is through marker regression. That is, we split individuals
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into groups according to the genotype at each marker. We next perform a hypothesis test,
either a t-test or an ANOVA, depending on the number of genotypes, to determine whether
there are differences in the mean value of the phenotype, y between individuals in different
genotype groups. This process may be repeated for each locus in the association analysis.
This approach is relatively simple, and easily incorporates additional covariates. However,
when using this approach, it is necessary to exclude individuals with missing data. In addi-
tion, this method does not take into account the location of a particular locus in relation to
other loci and only considers one QTL at a time.
6.2.2 Interval Methods
Interval methods improve upon earlier methods for identifying QTL associations. The major
innovation of interval methods was to move beyond the evaluation of single loci in isolation
and incorporates the spatial relationships between genetic loci into association mapping.
Interval methods take missing genotype data into account and also incorporate the marker
location and relationships by making use of a genetic map of typed loci and interpolating
between them [100]. For this model, we assume a single causal QTL. For each position
in the genome, one locus at a time is posited as the putative QTL, and we assume the
phenotype y ∼ N(µz, σ). If the QTL genotype is BB/AB, we let x = 1/0. Given genotypes
at linked markers, we assume y is distributed as a mixture of normal distributions, with
mixing proportion Pr(z = 1|marker data), such that:
QTL genotype
M1 M2 BB AB
BB BB (1− rL)(1− rR)/(1− r) rLrR/(1− r)
BB AB (1− rL)/rr/r rL(1− rR)/r
AB BB rL(1− rR)/r (1− rL)rR/r
AB AB rLrR/(1− r) (1− rL)(1− rR)/(1− r)
M1 and M2 represent two different markers, and rL and rR represent two different alleles.
If we let pi = Pr(zi = 1|marker data) and assume yi|zi ∼ N(µzi, σ2), we may conclude that:
Pr(yi|marker data, µ0, µ1, σ) = pif(yi;µ1, σ) + (1− pi)f(yi;µ+ 0, σ) (6.10)
where f(y;µ, σ) = exp[−(y − µ)2σ2]/√2piσ2 and the log likelihood is:
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l(m0, µ1, σ) =
∑
i
logPr(yi|marker data, µ0, µ1, σ) (6.11)
The maximum likelihood estimates (MLEs) of µ0,mu1, σ are values for which the log like-
lihood function is maximized. The maximum values for µ0,mu1, σ may be determined by
utilizing the expectation-maximum algorithm [34].
The strength of evidence for the presence of a QTL at a particular location is determined
by a LOD score, where:
LOD(γ) = log10 likelihood ratio of QTL at position γ to no QTL (6.12)
= log10{Pr(y|QTL atγ, µˆ0, µˆ1, σˆ)
Pr(y|no QTL, µˆ, σˆ) } (6.13)
Assuming a single QTL at position γ, µˆ0γ, µˆ1γ, σˆγ are the MLEs.
The advantages to interval mapping are that this method takes into account missing
data, allows examination of positions between markers, and gives improved estimates of
QTL effects. Disadvantages include increased computation time and that QTLs are still
considered one at a time.
6.3 GENOME WIDE ASSOCIATION STUDIES (GWAS)
The development of cost-effective methods for genotyping larger and larger numbers of single
nucleotide polymorphism (SNP) markers together with the development of dense maps of
genetic loci within the human genome have made possible large-scale genetic association
studies involving comprehensive genome-wide surveys, referred to as genome-wide association
studies (GWAS). GWAS further exploit the spatial relationships between genetic loci that
are spaced in close proximity along the chromosome. Such loci are said to be in linkage
disequilibrium (LD), with a higher probability of being inherited together.
Several high-profile genome-wide association studies (GWAS) has been widely used to
detect novel genetic associations in complex diseases [124, 41, 115]. The GWAS approach
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is particularly advantageous because it provides greater power to find disease-associated
genetic variants than conventional linkage studies [64], and also provides a way to identify
previously unsuspected potentially causal genetic loci, compared to earlier candidate gene
studies [113]. Along with the development of GWAS technology, new statistical methods
have arisen to analyze GWAS output.
6.3.1 Multiple Linear Regression for GWAS
In quantitative genetics, a multiple linear regression model is often used to describe the
relationship between phenotypes and genetic markers. One advantage of this model is that
all marker effects may be estimated simultaneously and then used to perform hypothesis
testing to identify the QTL signal. A typical regression model is:
yi = β0 +
p∑
j=1
xijβj + ei (6.14)
where yi (i = 1, ..., n) is the phenotypic value of the i
th individual in the mapping population,
β0 is the intercept, xij is the genotypic value of the j
th marker for individual i, βj is the effect
of marker j, and ei is the random error assumed to follow a normal distribution N(0, σ
2
e)
with mean zero and variance σ2e independently for i = 1, ..., n. The genotype, xij, is defined
as:
xij =

1 if genotype is AA
0 if genotype is AB
−1 if genotype is BB
(6.15)
For QTL mapping with a dense set of markers, as in GWAS, we are interested in estimating
the effects of markers, β = {β1, ..., βp} and identifying markers in linkage disequilibrium
(LD) with QTLs.
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6.3.2 Limitations of Multiple Linear Regression for GWAS
Ordinary least squares (OLS) is a statistical method used to estimate regression coefficients.
In the case of QTL mapping, there are several problems with this method. Although OLS
gives an unbiased estimate of regression coefficients, there is often a great deal of variation,
which leads to inaccuracy in predicted values. In addition, OLS is not available in situations
where the number of exploratory variables is larger than the number of observations, the
p > n problem. In GWAS, it is common to have a dense set of SNP markers that is much
larger than the number of individuals ascertained for analysis. In this case, most of the SNP
markers assayed have minimal effects on the phenotypic trait studied. This results in a loss
of power, when all SNP markers are considered in a multiple linear regression QTL mapping
analysis. In practice, multiple linear regression is seldom used for all but the simplest genetic
association studies. Instead, univariate linear regression is used repeatedly on each marker
across the genome to avoid the p > n problem and analytical intractability inherent in
estimating the for such a large regression analysis. However, splitting the multivariate
regression problem into a series of univariate regression analyses results in a large number
of statistical tests necessitating adjustment for multiple testing. For this reason, it is often
useful to obtain a sparse model to increase the analytical power of the QTL mapping and
avoid the computational pitfalls involved in multivariate regression to solve for a large number
of .
6.3.3 Sparse Regression for GWAS
6.3.3.1 Ridge Regression Ridge regression is a form of penalized multiple linear regres-
sion [72]. Ridge regression adopts the l2 norm penalty function, λ
∑p
j=1 β
2
j . The regression
coefficients, β = {β1, ..., βp}, are estimated by minimizing the penalized sum of squares∑n
i=1(yi−β0−
∑p
j=1 xijβj)
2 +λ
∑p
j=1 β
2
j . The penalty function, λ
∑p
j=1 β
2
j , Ridge regression
is a specialized case of regularized regression that puts constraints on the size of coefficients
to control large variances associated with resulting estimates. It works by “shrinking” the
effect of redundant variables, such as redundant genetic markers, by imposing a penalty on
the size of their coefficients. In addition, ridge regression prevents any one regression coef-
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ficient from getting very large and thus protects against overfitting and the high variance
that often result from multiple linear regression with highly correlated variables.
6.3.3.2 LASSO regression Lasso regression was developed as a method of variable
selection, and is particularly useful in addressing the p > n problem. In lasso regression, the
regression coefficients, β = {β1, ..., βp}, are estimated by minimizing the penalized sum of
squares
∑n
i=1(yi−β0−
∑p
j=1 xijβj)
2 +λ
∑p
j=1 |βj|. The sum of absolute values, the so-called
l1 norm of the regression coefficients, λ
∑p
j=1 |βj| is the penalty function, and λ ≥ 0 is the
shrinkage factor, specified at the onset. When the penalty function is added to the residual
sum of squares and λ > 0, lasso is able to shrink the least squares estimators toward zero
and thereby decrease their variance. This approach is useful for GWAS, where only a small
number of SNP markers are related to the phenotype of interest. However, lasso has several
drawbacks compared to ridge regression. First, when the explanatory variables are collinear,
lasso will select only a single variable at random from a group of highly correlated variables.
This is a problem as GWAS are performed with densely spaced SNP markers, that are often
highly correlated and in linkage disequilibrium. Second, when p > n, the largest number of
explanatory variables that may be selected from the model is n, which may lead to the loss
of important variables and interacting loci in genetic association studies.
6.4 INTRODUCTION TO TEMPORALLY-SMOOTHED LASSO (TESL)
6.4.1 A Local Autoregressive Model for Dynamic Traits
While standard lasso addresses the problem of selecting disease-associated SNPs from a
large number of SNPs, it does not account for the correlation across d-traits at many time
points. To address this critical gap, we first use a local autoregressive model to characterize
the temporal correlation across the T time points in the d-trait. We then incorporate this
information within our algorithm, termed temporally-smoothed lasso (TESL) [97]. That is,
we incorporate the parameters of the local autoregressive model into a structured penalized
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regression method in order to find the regression coefficients.
The assumption of the local autoregressive model is that each d-trait is modeled locally,
as a function of the trait value at the previous time point. Assuming a linear model for local
temporal dependency, and given measurements of the d-trait at two adjacent time points t
and t+ 1, 1 ≤ t < T , we have:
yt+1 = αtyt + α
0
t1 + t, (6.16)
where the αt represents the slope for the multiplicative dependency of d-trait value at time
t+1 on the value at the previous time point, α0t corresponds to the intercept, 1 is a vector of
1’s of length N , and t is an N -vector of the noise terms with mean 0 and constant variance.
The parameters αt in the above model describes the local linear dependency, and the set
{αt’s for t = 1, . . . , T −1} represents the overall shape in the d-trait. We note that although
a linear relationship is assumed locally for adjacent time points, the set of models described
by αt’s does not assume any particular functional form globally for the d-traits, and can
capture a wide variety of non-stationary dynamic trends, including locally-linear, logistic,
and cyclic trends. This flexibility is an improvement upon methods that assume parametric
functions for the shape of the trajectory [181].
After centering the d-trait data yt by subtracting the mean y¯t to obtain y
c
t = yt− y¯t, the
parameters αt and α
0
t in Eq. (6.16) can be estimated from the mean-centered data, using
the standard least square method as follows:
αˆt = argmin (y
c
t+1 − αtyct)> · (yct+1 − αtyct).
We are only concerned with the slope parameters αt’s since they represent the temporal
dependency of the magnitudes of a d-trait between two time points. The estimate for αt is
given as:
αˆt =
(yct)
> · yct+1
(yct)
> · yct
. (6.17)
The estimates of αt’s describe the local temporal dependencies for each d-trait. The αt’s
are then incorporated into the penalty in TESL. Recall that the αt’s encode the strength of
dependence of a d-trait between two adjacent time points.
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6.4.2 Formulation and Parameter Estimation for the Temporally-Smoothed
Lasso
In TESL, we use the αt’s to design a penalty for regularized regression that enforces a
temporal structure in the estimated association strengths βt’s. The additional penalty is
added to the lasso objective function as shown below:
Bˆ = argmin
∑
t
(yt −Xβt)>(yt −Xβt) + λ
∑
t
‖ βt ‖1 +γT (B), (6.18)
where T (·) denotes the autoregressive fusion penalty:
T (B) =
T−1∑
t=1
‖ βt+1 − αˆtβt ‖1 . (6.19)
The regularization parameter λ controls the sparsity of the estimated βt. A larger value
of λ yields a solution that is more sparse while a smaller value of λ yields a solution that
has fewer non-zero elements. The regularization parameter γ on the autoregressive fusion
penalty controls the difference in association strengths between βt+1 and αˆtβt. A large
value of γ encourages this difference to be zero. This implies that the non-stationary linear
dependencies between the d-traits at two adjacent time points t and t + 1, as described
by the local autoregressive model, are reflected in the temporal dependencies between the
association strengths βt+1 and βt through the parameter αˆt. For instance, if there is a large
increase between the d-trait values at time t and t+ 1, then αt will be a large positive value,
and there will be a noticeable difference in the association strengths βt+1 and βt. Both
regularization parameters λ and γ can to be selected via cross-validation.
We require a fast optimization procedure for this problem since a genome-wide scan
contains a huge number of SNPs. While this problem is convex, the autoregressive fusion
penalty poses a challenge to attaining efficient optimization because it is not smooth. Thus,
we use the smoothing proximal gradient method [23] whereby the strategy is to reformulate
the autoregressive fusion penalty via the dual norm to decouple the non-separable terms.
Then, a smooth approximation to the reformulated penalty is derived. The result is an
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objective function with a smooth square loss term, the smooth approximation to the autore-
gressive fusion penalty and the non-smooth lasso penalty. Since the reformulated objective
consists of simply a smooth component and the non-smooth lasso penalty, we can optimize
this efficiently with the fast iterative shrinkage-thresholding algorithm (FISTA) [11].
6.4.3 Selection of Regularization Parameters
To select the best model, we need to determine the optimal values for the two regularization
parameters: λ for the lasso penalty and γ for the autoregressive fusion penalty. The stan-
dard procedure for selecting these regularization parameters is to do cross-validation. This
has also been described in the setting of penalized regression for genome-wide association
mapping [183]. We split the data into a training set (90%) and a test set (10%) and do
cross-validation to select the (λ, γ) regularization parameter set with the lowest test error.
Once we obtain the βt’s from the best model, the selected SNPs were those with a non-zero
regression coefficient (association strength). We then reestimate the regression coefficients
using only the selected variables with standard least squares, which removes the bias imposed
by the penalties.
6.4.4 Simulation Study
We demonstrate our method on simulated datasets, and compare its performance with those
from the standard univariate association test and lasso that do not take into account temporal
structures in the d-traits.
6.4.4.1 Experimental Setup of Simulations We simulated datasets as follows. In
order to generate the genotype data, we first selected a segment of 50 SNPs randomly from
chromosome 7 of HapMap CEU panel [161] after removing the SNPs with MAF less than
0.10. In addition to the 60 individuals in the HapMap CEU panel, we generated additional
90 individuals by randomly mating the original 60 individuals to obtain genotypes for 150
individuals in total. Assuming that observations for a d-trait are obtained over 10 time
points, we generated the true association strengths by randomly selecting three SNPs and
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setting the association strengths for these SNPs to non-zero values that vary linearly or
cyclically over time. We set the association strengths for all of the other SNPs to zero. For the
linear d-trait, the association strength βj1 of each association SNP at the first time point was
randomly drawn from a uniform distribution [0.05, 0.1], and the association strengths of the
same SNP at subsequent time points were set to βj1× t, where t = 2, . . . , 10. For the cyclical
dynamic trait, we assume that the association strength of each SNP changes according to a
sinusoid functional form with 1.5 cycles and with the peak amplitude randomly sampled from
a uniform distribution [0.80, 0.85]. Given these genotypes and true association strengths, we
generated the d-trait values using a linear model with noise distributed as N(0, 1.0). In our
simulation study, we assume that all of the temporal correlation in the d-trait is induced by
the temporally changing genetic effects.
6.4.4.2 Illustrative Examples of Dynamic-Trait Associations In order to illustrate
the genetic effects on a d-trait, the simulated d-trait data under the scenario of linear growth
are shown in Figures 6.1A-D. While Figure 6.1A shows the d-trait trajectories for all of
the 150 individuals in a single simulated dataset, those same individuals are grouped into
three subsets according to the genotypes of the true association SNPs in Figures 6.1B-D.
The thick blue curves in Figures 6.1B-D indicate the mean trajectories within the group.
Figure 6.1B shows individuals with no mutations in any of the three association loci. Since
these individuals do not possess the genetic variants that can drive a temporal change in
the d-trait, the trajectories do not show any trend over time. As we introduce one or
two mutations in the genetic loci, a trend of linear growth starts emerging as shown in
Figure 6.1C. Figure 6.1D shows those individuals with more than three mutations, and this
pattern of linear growth becomes more apparent.
Given the d-trait data in Figure 6.1A simulated from the genotype data and the true
association strengths in Figure 6.1E, we perform a d-trait association mapping using a uni-
variate association test and lasso applied to each time point separately as well as our proposed
method, and show the results in Figures 6.1F-H, respectively. When the true association
signals are very weak at the early time points, all of the methods are unsuccessful in de-
tecting the signal. However, the results from univariate analysis and lasso contain many
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false positives at these early time points, whereas our method has significantly fewer false
positives. As the true association signals increase over time, our method starts detecting it
at earlier time points for the SNP on the third row than other methods, because it can take
into account the temporal correlation and infer from the observations at the adjacent time
points that the weak signal is indeed a true association.
Similarly, an illustration of the simulation scenario with a cyclical dynamic is shown in
Figure 6.2. The d-trait values have a cyclical trajectory over time in Figures 6.2C and D,
because of the periodic change in the genetic effects of the association variants as shown in
Figure 6.2E. When the individuals have no mutations at any of the three association SNPs,
the d-trait measurements do not show a cyclic trend, as can be seen in Figure 6.2B. Overall,
the association results show that our method in Figure 6.2H finds fewer false positives than
the univariate test in Figure 6.2F and lasso in Figure 6.2G. When the association signal is
weak between the peak and valley of the cycle, our method is able to borrow information from
the adjacent time points and infer the presence of associations, whereas the other methods
simply miss the signals.
6.4.4.3 Accuracies for Detecting True Associations We perform a systematic and
quantitative comparison of the performance of different association analysis methods in terms
of type I errors and powers for detecting true associations by generating 50 simulated datasets
as described above and averaging the results over these datasets. Assuming that association
strengths are indicated by -log(p-values) for univariate tests and the absolute values of the
estimated regression coefficients for lasso and our proposed method, we sort the estimated
association strengths and compare the top 5% values of the sorted list with the list of known
true associations to compute type I errors and powers. The average type I errors and powers
over time are shown in Figures 6.3A and B for the scenario of linear dynamic. Across all
time points, our proposed method has significantly lower type I errors and higher powers
than other methods that do not take advantage of the temporal correlation structure in the
d-traits. This gap in the performance is significantly greater at early time points when the
association signals are weak. Thus, our method can be potentially used to detect the genetic
effects of the associated variant on a d-trait at an early stage for a diagnostic purpose.
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For the scenario of a cyclic dynamic, we show the type I errors and powers averaged
over 50 simulated datasets in Figure 6.4. Again, our method outperforms other methods
across all time points. Especially when the association signals are weak between the peak
and valley of each cycle, the performance gap is significantly greater. This is because our
method can learn the presence of associations between peaks and valleys by exploiting the
temporal correlation in the d-trait.
We vary the number of association SNPs to 3, 7, and 10, and compare the performance
of different association methods in Figure 6.5, under the scenario of linear dynamic. Type
I errors are shown in Figures 6.5A-C for the number of association SNPs 3, 7, and 10,
respectively, and powers are shown in Figures 6.5D-F. The results are averaged over 50
simulated datasets, and top 10% with the highest estimated association strengths are used.
Our method has significantly lower type I errors and powers than any other methods across
all time points. Although the performance of all methods tends to increase over time as
the association strengths of the association SNPs increase, our method can still detect the
associations significantly better than other methods at the early time points.
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Using a simulated dataset for a d-trait with a linear dynamic. A: Trait measurements over 10 time points
for 150 individuals. B: Trait measurements for the individuals with no mutations in all of the three
causal genetic loci. These are unaffected individuals with no specific trend in the trajectories over time.
The thick blue curve indicates the mean trajectory among these individuals. C: Trait measurements
for the individuals with one or two mutations on causal genetic loci. The trend of a linear increase
starts to emerge as these mutations drive the temporal change in the d-trait. D: Trait measurements
for the individuals with more than three mutations on causal genetic loci. As more causal mutations
are introduced, the linear trend is stronger with steeper slope than in Panel C. E: True association
strengths used to generate this simulation dataset. F: -log(p-values) from single-SNP association tests.
G: The absolute values of the estimated association strengths from lasso. H: The absolute values of the
estimated association strengths from d-trait lasso.
Figure 6.1: Illustration of d-trait association mapping.
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Using a simulated dataset for a d-trait with a cyclic dynamic. A: Trait measurements over 10 time points
for 150 individuals. B: Trait measurements for the individuals with no mutations in all of the three causal
genetic loci. These are unaffected individuals with no specific trend in the trajectories over time. The
thick blue curve indicates the mean trajectory among these individuals. C: Trait measurements for the
individuals with one or two mutations on causal genetic loci. The cyclic trajectory starts to emerge as
these mutations drive the temporal change in the d-trait. D: Trait measurements for the individuals with
more than three mutations on causal genetic loci. As more causal mutations are introduced, the cyclic
trend is stronger with higher peaks and lower valleys than in Panel C. E: True association strengths
used to generate this simulation dataset. F: -log(p-values) from single-SNP association tests. G: The
absolute values of the estimated association strengths from lasso. H: The absolute values of the estimated
association strengths from d-trait lasso.
Figure 6.2: Illustration of d-trait association mapping.
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Data were simulated assuming a linear dynamic in d-traits. A: Type I errors over the 10 time points.
B: Powers. Results were averaged over 50 simulated datasets.
Figure 6.3: Comparisons of different methods for a d-trait association analysis using simu-
lated datasets.
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Data were simulated assuming a cyclic dynamic in d-traits. A: Type I errors over the 10 time points.
B: Powers. Results were averaged over 50 simulated datasets.
Figure 6.4: Comparisons of different methods for a d-trait association analysis using simu-
lated datasets.
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Data were simulated assuming a linear dynamic in d-traits. Type I errors over the 10 time points are
shown for A: S=3, B: S=7, C: S=10. Powers over the 10 time points are shown for D: S=3, E: S=7,
F: S=10. Results were averaged over 50 simulated datasets.
Figure 6.5: Comparisons of different methods for a d-trait association analysis using simu-
lated datasets when the number of causal loci S varies.
6.4.4.4 Prediction Accuracy Finally, we compare the performance of the different
methods in terms of the prediction errors in Figure 6.6. We generate test data for additional
100 individuals, and compute the squared differences between the predicted values based on
the estimated regression coefficients and the observed values. The prediction error is defined
as an average of these squared differences over 100 individuals in the test set. We repeat
this process for 50 simulated datasets, and show the prediction errors averaged over these
datasets in Figures 6.6A and B for the two scenarios of dynamic growth and cyclic trend,
respectively. We find that our method has significantly lower prediction errors than lasso
that does not combine information across time.
6.4.4.5 Non-dynamic Genetic Effects in Dynamic Trait Association While the
simulation studies above considered the d-trait association scenarios with dynamic genetic
effects, where the size of genetic effects on d-traits changes over time, we now consider
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A: A linear dynamic in d-traits. B: A cyclic dynamic in d-traits. Results were averaged over 50 simulated
datasets.
Figure 6.6: Test errors using simulated datasets.
association scenarios with non-dynamic effects of SNPs on d-traits such as constant genetic
effect sizes over time or genetic effects only at a single time point. In order to simulate data,
we obtained 721 SNPs on chromosome 22 for 721 individuals from HapMap 3 data [160] after
filtering out SNPs with MAF less that 0.05 and SNPs with pairwise correlation greater than
0.88 between neighboring SNPs. Then, assuming three association SNPs and the number of
time points T = 5, we set the true values for association strengths as follows. For the case
of constant genetic effects over time, the strength of each of the three association SNPs was
sampled randomly from the uniform distribution [0.1, 0.5]. For the case of a genetic effect
at a single time point, the association SNPs were assumed to influence the d-trait only at
t = 3, and the association strengths were randomly sampled from a uniform distribution [0.1,
0.8]. All of the results were obtained by choosing 360 samples randomly as a training set,
performing 10-fold cross-validation to select the regularization parameters, and computing
the prediction errors on the remaining 361 samples.
In Figure 6.7, we compare the performance of our method with the standard lasso in terms
of the type I errors, powers, and prediction errors averaged over 50 simulated datasets. The
left and right columns in Figure 6.7 show results from each of the two simulation scenarios,
constant and single-time-point genetic effects, respectively. We find that our new method
gives lower type I errors than lasso in both of the scenarios (the top row in Figure 6.7).
This shows the benefit of the smoothing effect of the autoregressive fusion penalty that sets
the association strengths of SNPs with no associations to zeros across time points. For the
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scenario of the constant genetic effects, this smoothing effect of our penalty also slightly
increases the power, whereas it slightly decreases the power for the case of genetic effects
at a single-time point (the middle row in Figure 6.7). For both of the scenarios, the TESL
method gave lower prediction errors than lasso, showing that the benefit of the smoothing
effect of our method generally outweighs their potential disadvantages.
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A: Genetic effects of association SNPs were assumed to be constant across all time points. B: Association
SNPs were assumed to influence the d-trait only at a single time point (t=3). Type I errors, powers,
and prediction errors are shown in the top, middle, and bottom rows, respectively.
Figure 6.7: Results on simulated datasets under scenarios for non-dynamic genetic effects.
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6.4.4.6 Null Distribution To assess the type I error of our method, we have performed
null simulations and computed the type I error for both TESL and standard lasso. For this
experiment, we used the 721 individuals with 721 SNPs on chromosome 22 from HapMap
3 data [160] with MAF > 0.05 previously described in Section 6.4.4.5. To simulate the null
distribution, we set the association strengths for all SNPs at all time points to zero so that
there are no true associations. We then generated the d-trait values using a linear model
with noise distributed as N(0, 1.0). We compare the type I error between our method and
standard lasso. After thresholding the association strengths at different levels 0.15, 0.1, 0.05,
and 0, the type I error is shown in Figures 6.8A-D, respectively. These results were averaged
over 50 simulated data sets. As can be observed from Figure 6.8D, the type I error < 0.05. In
addition, the magnitude of the association strengths βt of the false positives are very small.
At |βt| > 0.15, as shown in Figure 6.8A, the type I error is zero at all time points.
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Figure 6.8: Type I error for different regression coefficient thresholds.
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6.4.4.7 Computation Time In order to assess the feasibility of running TESL on a
large dataset, we measure the computation time for running our method and the standard
lasso on datasets of varying sizes and show the results in Figure 6.9. In Figure 6.9A, we
vary the number of SNPs while fixing the number of time points at 10. In Figure 6.9B, we
vary the number of time points, fixing the number of SNPs at 1000. The results show that
our method can efficiently handle datasets of thousands of SNPs and up to a hundred time
points in a few minutes. For example, a dataset with 8000 SNPs measured over 10 time
points could be handled in less than 7 minutes. The project page along with available code
for TESL may be accessed at: http://cogito-b.ml.cmu.edu/dynamictraits/.
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7.0 GENETIC ASSOCIATIONS AND DYNAMIC ASTHMA ENDOTYPES
7.1 INTRODUCTION
Current GWAS are limited in that they only consider associations between genotypes and
static phenotypes — snapshots of traits at a single time point — when more information
is often available. For example, clinical trials typically record longitudinal traits such as
BMI [31], triglycerides [192] and blood glucose levels [129]. We refer to a longitudinal trait
that changes value over time as a dynamic trait or d-trait. A particular genotype can cause a
trait not only to vary across individual, but also to change over time for the same individual;
and the potential for such information, if available, to identify disease-related genes can be
significant. If d-trait data is accessible, it is desirable to use this information to identify
genetic loci that drive the temporal evolution of the trait. Such a method of association
analysis can utilize the complete trajectory for a particular clinical trait which increases the
power of GWAS. To provide some insight into the intuition behind this problem, consider
the situation where two individuals with different genotypes have the same measurement of
a trait at a specific time point (Fig. 7.1A). In this situation, GWAS would not detect any
contributing genetic variations. However, these individuals may have completely different
trajectories for this trait (Fig. 7.1B). Thus, using dynamic information, it is more probable
that these variations will be detected.
The concept of finding associations between regions of the genome and longitudinal traits
has been previously investigated. Techniques such as repeated measures analysis [135, 28,
32, 129], averaging of traits across time points [79] and identifying principal components
[101] to capture the temporal information of complex traits have been used with a modest
degree of success. However, such techniques may result in loss of information, particularly
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the information contained in the trajectory of a particular trait. To address this problem,
more sophisticated methods have been proposed, such as non-parametric approaches based
on Legendre orthogonal polynomials [31] and adaptive splines [192], to model longitudinal
data. This is a promising direction, but these methods are different from our proposed
method in that they do not explicitly impose the sparsity of associations between genotype
and phenotype, which is crucial in elevating the stringency of detection in high-dimensional
(large number of candidate predictors) and high-noise cases. In the literature of quantitative
trait locus (QTL) mapping for linkage analysis, the problem of finding a linkage between a
genetic locus and a d-trait has been broadly termed as functional mapping [111,182,172] and
the standard mixture model for QTL mapping for a static trait has been extended to address
this problem. However, the mixture model for functional mapping was designed for linkage
analysis, and does not extend to the general problem of association mapping of unrelated
individuals with a relatively dense set of genetic markers.
7.2 APPLICATION OF TESL TO A COHORT OF ASTHMATIC
CHILDREN
7.2.1 Description of Study Subjects and Dynamic Trait
The current study utilized GWAS data from 466 non-Hispanic white children who partic-
ipated in the Childhood Asthma Management Program (CAMP). Characteristics of the
study subjects are presented in Table 7.1. CAMP was a multi-center randomized, double-
masked clinical trial of the long-term effects of three inhaled treatments for mild to moderate
asthma, with 1,041 subjects enrolled and followed for a period of 48 months. Inclusion cri-
teria and protocols for collection of baseline phenotypic data have been described in detail
elsewhere [82,81].
As part of the study, several measures of pulmonary function were evaluated at regular
intervals. We chose one of these measures, the forced expiratory volume measured after the
administration of an inhaled bronchodilator medication (post-bronchodilator FEV1) to use
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Figure 7.1: Illustration of association analysis.
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study month FEV1
Mean (SD) [Range]
0 103.0 (12.8) [62, 154]
2 104.9 (13.1) [67, 145]
4 104.3 (12.8) [46, 151]
12 104.4 (12.6) [50, 151]
16 103.0 (12.6) [46, 136]
24 103.3 (12.4) [66, 137]
28 103.0 (12.2) [62, 141]
36 103.1 (13.0) [48, 142]
40 103.2 (12.2) [66, 143]
48 102.7 (12.9) [56, 142]
FEV1 = One-second forced expiratory volume. SD = Standard deviation.
Table 7.1: Characteristics of FEV1 D-trait Over Time.
for association analysis. The post-bronchodilator FEV1 is a sensitive measure of the degree of
airway obstruction present in asthmatics after the administration of a corrective medication.
For this reason it is thought to be representative of an asthmatic child’s intrinsic level of
lung function that is not responsive to medical therapy [137]. The units of measurement for
the FEV1 are typically in liters. However, as the expected value for the FEV1 can vary with
height, the FEV1 is typically reported as a percentage of the value predicted for a certain age
and height, which is what we used for the current study. In the original CAMP study, study
subjects were evaluated at regular intervals and measures of pulmonary function, including
the FEV1, were obtained. Over the 48-month period of the study, each subject’s FEV1
was measured a total of 10 times, approximately once every four months. The exact study
months are listed in Table 7.1. We adjusted the FEV1 trait for baseline imbalances in age,
sex, height, height squared and the clinical location from which the subjects were recruited.
The residuals obtained after making these adjustments were used as inputs to TESL.
7.2.2 Preprocessing of Genetic Data
Of the original CAMP participants, 968 provided DNA and 299 provided RNA for genetic
studies as part of the CAMP Genetics Ancillary Study. Of the 968 participants who pro-
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vided DNA, 466 were non-Hispanic white children. The Institutional Review Boards of the
Brigham and Women’s Hospital (Boston, MA) and of the other CAMP study centers ap-
proved this study. Informed assent and consent were obtained from the study participants
and their parents to collect material for genetic studies.
Details of genotyping and quality control have been described previously [70]. Genome-
wide genotyping for CAMP subjects was performed on the HumanHap550 Genotyping
BeadChip or Infinium HD Human610-Quad BeadChip by Illumina, Inc (San Diego, CA)
at the Channing Laboratory. Data from those subjects genotyped using Illumina tech-
nologies was combined into a primary dataset of SNPs having missingness < 1%, passing
Hardy-Weinberg Equilibrium (HWE) (p-value threshold of 1x10−3), and having minor allele
frequency (MAF)>0.05.
To expand the association results, imputation of all SNPs available in the June 2010
release of the 1000 Genome Project (1000GP) data using MaCH [176] was performed for
the genotype data. A set of 6,216,972 imputed SNPs had a MAF>0.05 and a ratio of
empirically observed dosage variance to the expected (binomial) dosage variance greater
than 0.5, indicating good quality of imputation.
We performed pruning of highly correlated SNP markers. PLINK was used to prune
SNPs based upon the degree of linkage disequilibrium, with the goal of generating a pruned
subset of SNPs in approximate linkage equilibrium to each other. The multiple correlation
coefficient for each SNP being regressed simultaneously on all other SNPs within a sliding
window of 150 SNPs was calculated, and SNPs were pruned if the calculated multiple cor-
relation coefficient was below the variance inflation factor (VIF) threshold (1.85). The total
number of SNPs remaining after this step was 306,025. A genomic inflation factor (GIF)
was obtained for each time point of the FEV1 from unadjusted Chi-square values for allelic
association. The GIF was 1.000, indicating minimal population stratification. To improve
the computational time required for the genome-wide analysis, we divided each chromosome
into sections of approximately 3500 SNPS and then ran our method on each chromosome
section. All genetic and phenotypic data are available in the database of Genotypes and
Phenotypes (dbGaP) accession phs000166.v2.p1.
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7.3 ANALYSIS OF THE CAMP COHORT WITH TESL
We applied the TESL to a GWAS of SNPs and FEV1 values from non-Hispanic white par-
ticipants in the CAMP study. To select the regularization parameters for TESL, we chose
a range of λ and γ parameters and examined the cross-validation test error. We calculated
the cross-validation test error for each pair (λ, γ) of the regularization parameters, and se-
lected the values resulting in the minimum cross-validation test error. Running TESL on
each section for a single regularization parameter set (λ, γ) took approximately 1.3 minutes.
Thus, cross-validating over a possible 200 parameter sets yielded a runtime of approximately
5 hours per section.
For the optimal regularization parameter set (λ, γ), TESL identified 271 non-zero asso-
ciations (SNPs with non-zero regression coefficients for at least one time point) from 306,025
SNPs tested. Although the 271 associations were spread across the genome, several chromo-
somes contained multiple non-zero associations, including chromosomes 2, 8, 9, 12 and 16.
To prioritize the non-zero associations, we calculated the mean of the absolute values of the
association strengths (regression coefficients) across all time points to generate a single asso-
ciation strength value for each SNP. We ranked these values in order of magnitude and used
the values to prioritize the non-zero associations. A Manhattan plot of mean association
strengths over time for TESL is shown in Figure 7.2. Because we used a sparse regression
method, the majority of the association strengths in the Manhattan plot were zero, while
271 associations were non-zero. The top 10 associations as ranked by association strength
are displayed in Table 7.2.
7.3.1 Functional Analysis of Temporally-Smoothed Lasso Associations
In order to evaluate the functional significance of the non-zero associations, we performed
a gene ontology (GO) enrichment analysis on all genes neighboring the associated genomic
regions. The 271 non-zero associations were within 100 kb of 554 genes. We performed a
hypergeometric test to determine whether the set of genes neighboring significant associations
was enriched for specific biological processes (BP) compared to that expected for a randomly
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The black and gray striations denote different chromosomes.
Figure 7.2: Manhattan plot of mean association strengths for each chromosome.
selected set of genes. Genes annotated to GO terms received weights based on the scores of
neighboring GO terms, and significance scores of connected components were compared to
detect the most significant local terms within the GO hierarchy [1]. We found that the genes
neighboring non-zero associations were functionally enriched in multiple biological processes
of known relevance to asthma, including multiple pathways related to innate immunity and
inflammation (Table 7.3). The observation that our non-zero associations were in close
proximity to genes with functional relevance to asthma lends further support to the validity
of our method and its ability to detect asthma-relevant associations.
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SNP CHR BP MAF Mean |(βj)|
chr8:4233416 8 4233416 0.068 6.47
rs576967 9 1701524 0.061 4.76
chr12:94963945 12 94963945 0.075 3.26
rs10828784 10 18828279 0.29 3.18
chr9:91083694 9 91083694 0.058 3.17
chr12:19567609 12 19567609 0.070 3.16
chr9:124655498 9 124655498 0.10 3.14
rs7023886 9 114767890 0.13 3.05
rs2229320 16 10909244 0.14 3.03
chr16:66927184 16 66927184 0.10 2.97
Table 7.2: Top 10 significant SNPs from in CAMP dataset identified by TESL.
We next performed a targeted enrichment analysis on the genes neighboring the (cis-
acting) non-zero associations that demonstrated differential expression between different
alleles. We used a linear model to detect differences in gene expression levels between subjects
with different alleles, and select the genes with the highest level of differential expression (p-
value < 0.10) for enrichment analysis. Of 22,184 genes assayed on the microarray chip, 554
were within 100 kb of non-zero SNP associations and 43 of these were differentially expressed
between subjects with different alleles, with 37 having available GO annotations that could
be used for analysis.
We evaluated these 37 genes for functional enrichment in the BP ontology as described
above, and the top GO annotations detected by this method are presented in Table 7.4. We
detected several significant GO terms with established relevance to asthma pathogenesis,
such as the response to glucocorticoid stimulus (GO:0051384), which was underrepresented
in our set of genes. Glucocorticoid medications are one of the mainstays of asthma ther-
apy and numerous clinical trials highlight the benefits of these medications in children with
asthma [24]. The genes associated with this GO term were G protein-coupled receptor
83 (GPR83) on chromosome 11, and transcription factor AP-4 (TFAP4) on chromosome 16.
Both of these genes were located in cis to SNPs with non-zero associations and demonstrated
differential expression between subjects with different alleles. Another GO term relevant to
asthma pathogenesis was positive regulation of TGF beta production (GO:0071636), which
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was also underrepresented for our set of genes. The gene associated with this GO term
was glucosidase, beta (bile acid) 2 (GBA2), located on chromosome 9 and also differentially
expressed between subjects with different alleles. TGF beta has been liked to airway re-
modeling and the pathogenesis of asthma [45], so the presence of this GO term among the
significant annotations suggests a functional link between this genomic region and allelic
differences in asthma pathogenesis.
GO ID Term Annotated Significant Expected p-value
GO:0034122 negative regulation of toll-like receptor signaling 13 4 0.24 0.00014
GO:0050777 negative regulation of immune response 53 7 0.96 0.00025
GO:0002062 chondrocyte differentiation 69 7 1.26 0.00079
GO:0032695 negative regulation of interleukin-12 production 11 3 0.2 0.00153
GO:0009581 detection of external stimulus 101 8 1.84 0.00266
GO:0006953 acute-phase response 45 5 0.82 0.00299
GO:0006925 inflammatory cell apoptotic process 14 3 0.25 0.00322
GO:0034260 negative regulation of GTPase activity 14 3 0.25 0.00322
GO:0007062 sister chromatid cohesion 34 4 0.62 0.00636
GO:0030199 collagen fibril organization 36 4 0.66 0.00781
GO:0032088 negative regulation of NF-kappaB transcription 57 5 1.04 0.00826
GO:0006833 water transport 38 4 0.69 0.00946
GO:0071385 cellular response to glucocorticoid stimulus 22 3 0.4 0.01195
GO:1900449 regulation of glutamate receptor signaling 22 3 0.4 0.01195
GO:0021983 pituitary gland development 43 4 0.78 0.01452
GO:0048333 mesodermal cell differentiation 24 3 0.44 0.01521
GO:0048147 negative regulation of fibroblast proliferation 24 3 0.44 0.01521
GO:0019319 hexose biosynthetic process 67 5 1.22 0.01596
GO:0032873 negative regulation of stress-activated MAPK cascade 25 3 0.46 0.017
GO:0010862 positive regulation of pathway-restricted 26 3 0.47 0.01891
SMAD protein phosphorylation
The ‘Significant’ column refers to the number of significant genes associated with a particular GO term.
The ‘Expected’ column refers to the percentage of significant genes expected to be associated with a GO
term assuming a random distribution.
Table 7.3: Statistics for Significant GO Terms for Genes Neighboring Non-zero Associations.
7.3.2 Description and Functional Significance of Top SNP Association
The SNP with the largest association strength was located at chr8:4233416 (Table 7.2). The
FEV1 trajectory for this SNP is shown in Figure ??. For this SNP, subjects with different
alleles had very different trajectories over the 48-month duration of the study. Subjects
possessing two copies of the minor allele had relatively high values of the FEV1 (mean FEV1
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GO ID Term Annotated Significant Expected p-value
GO:2000278 regulation of DNA biosynthetic process 15 2 0.03 0.00056
GO:0050679 positive regulation of epithelial cell proliferation 114 3 0.24 0.00247
GO:0071695 anatomical structure maturation 40 2 0.09 0.00403
GO:0002040 sprouting angiogenesis 48 2 0.10 0.00577
GO:0006987 activation of signaling protein activity... 63 2 0.13 0.00976
GO:0030198 extracellular matrix organization 202 3 0.43 0.01206
GO:0051329 interphase of mitotic cell cycle 397 4 0.85 0.01415
GO:0045766 positive regulation of angiogenesis 89 2 0.19 0.01883
GO:0072203 cell proliferation involved in metanephros development 10 1 0.02 0.02345
GO:0071157 negative regulation of cell cycle arrest 10 1 0.02 0.02345
GO:0060041 retina development in camera-type eye 103 2 0.22 0.02474
GO:0008652 cellular amino acid biosynthetic process 104 2 0.22 0.02519
GO:0046479 glycosphingolipid catabolic process 11 1 0.02 0.02576
GO:0045601 regulation of endothelial cell differentiation 11 1 0.02 0.02576
GO:0071636 positive regulation of TGF-beta production 11 1 0.02 0.02576
GO:0090136 epithelial cell-cell adhesion 11 1 0.02 0.02576
GO:0043923 positive regulation by host of viral transcription 11 1 0.02 0.02576
GO:0051384 response to glucocorticoid stimulus 108 2 0.23 0.02701
GO:0015669 gas transport 12 1 0.03 0.02807
GO:0044319 wound healing, spreading of cells 12 1 0.03 0.02807
The ‘Significant’ column refers to the number of significant genes associated with a particular GO term.
The ‘Expected’ column refers to the percentage of significant genes expected to be associated with a GO
term assuming a random distribution.
Table 7.4: Statistics for Significant GO Terms for Differentially Expressed Genes.
= 140%) at the beginning compared to subjects with two copies of the major allele (mean
FEV1 = 103%) and heterozygotes (mean FEV1 = 100%). However, for subjects with two
copies of the minor allele, the FEV1 declined linearly during the study to levels similar to
those of subjects possessing two copies of the major allele (FEV1 = 115%, minor allele, FEV1
= 103%, major allele) and heterozygotes (mean FEV1 = 101%). Conversely, the subjects
with two copies of the major allele and the heterozygotes had relatively stable values of
FEV1 over the study period, that were consistently lower than the FEV1 values for subjects
with two copies of the minor allele.
The SNP chr8:4233416 is located on the short arm of chromosome 8, and upstream from
the gene for defensin β-1 (DEFB1). The DEFB1 protein is expressed in airway epithelial
tissue and has been found to play a role in host defense against respiratory pathogens [52].
Prior studies have linked polymorphisms in the gene for DEFB1 with an increased risk of
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asthma [108, 107]. Although we did not observe differential expression of DEFB1 between
subjects with different alleles, it is plausible that variation in the upstream region leads
to regulatory changes with an effect on DEFB1, such as enhanced degradation. Further
work will be necessary to validate these early findings in an independent population and to
characterize the functional significance of this variation.
This SNP and the associated d-trait trajectory serve to illustrate the advantage of TESL.
If we were to perform a cross-sectional analysis exploring associations between this SNP and
the FEV1 at discrete points in time, the potential to detect a significant association would
be reduced. However, because we were able to leverage the dynamic change in the trajectory
across time, we had increased power to detect this association. Furthermore, not only did
the value of the FEV1 vary between subjects with different allelic variants, but the trajectory
of the trait also varied among different subjects. Heterozygotes and subjects with two copies
of the major allele had a relatively stable FEV1 trajectory, while subjects with two copies
of the minor allele had an FEV1 trajectory that declined linearly over the duration of the
study period, suggesting that the variant exerts an effect on asthma pathophysiology that
occurs over an extended period of time.
7.3.3 Non-Zero Associations Correspond to Differences in Gene Expression
In order to investigate the functional significance of the associations identified by TESL, we
evaluated for the presence of differential gene expression levels between different allele types,
and associations with the FEV1 trajectory. Of the 554 genes we investigated, we found 6
genes with significant (adjusted p-value < 0.05) differences in expression after adjustment
for multiple testing (Table 7.5). Two of these genes were of particular interest due to their
putative role in asthma pathogenesis, and we have provided a detailed review of our findings
below.
One gene of interest was DENN/MADD domain containing 5B (DENND5B), located
within 100 kb of SNP marker rs7313158 on chromosome 12. For this gene, the SNP marker
rs7313158 was located approximately 100 kb downstream from the coding region of the
DENND5B gene. We found that subjects possessing two copies of the major allele had
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SNP Gene Chr Minor Allele Heterozygote Major Allele p-value Adj. p-value
Av. Expression Av. Expression Av. Expression
rs1752380 SELENBP1 1 7.24 7.23 7.32 0.0029 0.032
rs1752380 TUF1 1 7.87 7.84 7.77 0.016 0.089
rs2728436 PEX2 8 9.78 9.64 9.77 0.0027 0.0053
rs4741755 KIAA0020 9 9.42 9.39 9.46 0.012 0.037
rs7313158 DENNDB5 12 7.20 7.18 7.24 0.004 0.008
rs4026608 IRAK3 12 7.85 7.85 8.16 0.0075 0.03
Table 7.5: List of Genes With Differential Allelic Expression Patterns.
higher levels of expression of this gene compared to subjects with two copies of the minor
allele and heterozygotes (Benjamini-Hochberg (BH) adjusted p-value = 0.008) as shown in
Figure 7.4). Subjects with different alleles also had differences in their FEV1 trajectory over
time. Those with two copies of the major allele had relatively higher FEV1 levels early in the
course of the study (mean FEV1 = 104%, major allele, FEV1 = 103%, minor allele, FEV1 =
102%, heterozygote), but FEV1 levels for the major allele decreased over time (mean FEV1
= 102% at 48 months) (Fig. 7.4). Conversely, the FEV1 of subjects with two copies of the
minor allele and heterozygotes did not demonstrate this decline in FEV1 over time.
The rs7313158 SNP locus was associated with the DENND5B gene, which is located
on the reverse strand of chromosome 12. The eQTL locus is downstream from DENND5B,
and suggests the presence of a functional regulatory locus within this region. There are no
existing associations between the DENND5B gene and asthma or atopy, although variants
in the DENND1B gene have been associated with childhood asthma [147]. Like DENND1B,
DENND5B contains a GTPase binding domain, however it’s function in normal physiology
is not completely characterized [114].
Another gene that demonstrated differential expression for different alleles was the interleukin-
1 receptor-associated kinase 3 (IRAK3) gene, located within 100 kb of SNP marker rs4026608.
For the IRAK3 gene, subjects with the major allele had relatively higher levels of expression
of this gene compared to subjects with two copies of the minor allele and heterozygotes (BH
adjusted p-value = 0.03) (Fig. 7.5). Subjects with different alleles also had corresponding
differences in their FEV1 trajectory. Those with two copies of the major allele had con-
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A: Gene expression levels of DENND5B for subjects with different alleles for SNP rs7313158. Subjects
with two copies of the major allele (0) have relatively higher levels of DENND5B expression than subjects
with two copies of the minor allele (2) and heterozygotes (1), Benjamini-Hochberg (BH) adjusted p
= 0.008. B: Post-bronchodilator FEV1 trajectory for subjects with different alleles for SNP marker
rs7313158. At the beginning of the time course, the FEV1 for subjects with the major allele is relatively
higher than the FEV1 for subjects with the minor allele and heterozygotes. However, as time progresses,
the FEV1 for subjects with the major allele decreases and becomes more similar to that of subjects with
the minor allele and heterozygotes.
Figure 7.4: Gene expression for DENND5B and FEV1 trajectory for cis-associated eQTL
rs7313158.
sistently lower FEV1 values than those with two copies of the minor allele (mean FEV1 =
103%, major allele, mean FEV1 = 104%, minor allele at study onset; mean FEV1 = 101%,
major allele, mean FEV1 = 102%, minor allele at 48 months) (Fig. 7.5).
The rs4026608 SNP locus was associated with the IRAK3 gene, also located on chromo-
some 12. This SNP locus is located upstream from the IRAK3 gene, and may also indicate
the presence of a nearby regulatory factor for this gene. IRAK3 variants have previously
been implicated in asthma pathogenesis [8, 134]. A recent study has shown that IRAK3
can inhibit Toll-like receptor 2 (TLR2), leading to increased susceptibility to infections in
asthmatic patients [180], suggesting a role for this protein in mucosal immunity and the
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A: Gene expression levels of IRAK3 for subjects with different alleles for SNP rs4026608. Subjects with
two copies of the major allele (0) have relatively higher levels of IRAK3 expression than subjects with
two copies of the minor allele (2) and heterozygotes (1), Benjamini-Hochberg (BH) adjusted p = 0.03.
B: Post-bronchodilator FEV1 trajectory for subjects with different alleles for SNP marker rs4026608.
Throughout the duration of the study period, the FEV1 for subjects with the major allele is consistently
lower than the FEV1 for subjects with the minor allele and heterozygotes.
Figure 7.5: Gene expression for IRAK3 and FEV1 trajectory for cis-associated eQTL
rs4026608.
development of asthma and atopy.
7.3.4 Comparison of Temporally-Smoothed Lasso with Univariate and Lasso
Association Methods
We applied two other GWAS methods, univariate regression and standard lasso for compar-
ison. We first used univariate regression to identify associations between SNPs and FEV1
values. We evaluated for associations at each time point individually, and did not identify
any SNPs that reached genome wide significance (p-value < 5× 10−8) [128,2, 149,90,87].
We next used standard lasso to identify associations between SNPs and FEV1 values. A
Manhattan plot of the mean association strengths for lasso regression across time is shown
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in Figure 7.6. Standard lasso found fewer associations than TESL (92 vs. 271 non-zero
associations), indicating that lasso had a reduced sensitivity for detecting associations, com-
pared to TESL. However, there were 28 SNPs that were identified by both standard lasso
and TESL, depicted in Table 7.6.
The black and gray striations denote the different chromosomes.
Figure 7.6: Manhattan plot of all the mean association strengths across time for every
chromosome using lasso.
Among the SNPs identified by both lasso and TESL, rs10828784 on chromosome 10 had
the largest association strength. The FEV1 trajectory for this marker is shown in Figure 7.7A.
However, lasso was unable to identify any of the top 10 associations identified by TESL, such
as that for rs576967 on chromosome 9 and shown in Figure 7.7B. We believe that lasso was
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SNP CHR BP Mean |(β)| Mean |(β)|
lasso d-trait
rs12741361 1 149612957 1.25 2.65
rs1752380 1 149614370 0.61 2.32
rs1980769 1 96660789 0.31 1.99
rs9726107 1 166451806 0.26 2.05
rs6721668 2 37906399 0.40 0.95
rs11693474 2 83722702 0.30 0.30
rs956966 2 102954007 0.26 0.86
rs6745725 2 172163179 0.26 0.36
chr2:4100198 2 4100198 0.28 0.28
rs62134811 2 55032629 0.42 0.37
chr2:96998163 2 96998163 1.16 2.04
chr2:173923930 2 173923930 0.30 0.80
rs275510 5 6912895 0.61 2.16
rs4741755 9 2657929 0.33 2.52
chr9:25554159 9 25554159 0.33 2.25
rs13290170 9 8882736 0.45 1.75
chr9:120368912 9 120368912 0.30 0.95
rs10828784 10 18828279 2.98 3.18
rs12411340 10 66707498 0.98 2.01
rs11818488 10 66708116 0.92 2.10
chr11:24580358 11 24580358 0.29 1.76
rs1946151 16 53302612 1.51 2.70
rs1728778 16 67186352 0.49 1.88
rs7194083 16 9497354 0.91 1.44
rs13335305 16 10263717 0.25 0.86
rs1881220 16 84999403 0.24 1.95
rs1940289 18 951825 0.57 2.05
chr19:19145018 19 19145018 0.47 1.23
Table 7.6: List of positive associations identified by both lasso and d-trait.
able to detect an association with rs10828784 but not rs576967 due to differences in the rate
of change of the FEV1 trajectories. Although the FEV1 trajectories for subjects with different
variants of rs10828784 and rs576967 both demonstrate allelic variation, the trajectory for
subjects with different variants of rs576967 shows a much steeper rate of change between
time points than the trajectory for subjects with different variants of rs10828784. TESL was
able to capture this temporal fluctuation whereas standard lasso was not.
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A: Post-bronchodilator FEV1 trajectory for subjects with different alleles for SNP marker rs10828784.
This marker was identified as positively associated with FEV1 by both standard lasso and temporally
smoothed lasso. Across time, the subjects with two copies of the major allele have relatively stable
values of FEV1, that are lower than the heterozygotes and those with two copies of the minor allele.
The subjects with two copies of the minor allele have significantly more variability in the value of their
FEV1, and the trait experiences many more fluctuations over time compared to subjects possessing the
other alleles. B: Post-bronchodilator FEV1 trajectory for subjects with different alleles for SNP marker
rs576967. This marker was identified as positively associated with FEV1 only by temporally smoothed
lasso and not by standard lasso. Across time, the subjects with two copies of the major allele and the
heterozygotes have relatively stable values of FEV1. Conversely, the subjects with two copies of the
minor allele have a much greater point-to-point fluctuation in the FEV1 values that is identified by the
temporally-smooth lasso method.
Figure 7.7: Comparison of d-traits with associations detected by TESL and standard lasso.
7.4 DISCUSSION
Asthma is a disease that is characterized by chronic airway inflammation, airway hyperre-
sponsiveness and reversible airflow limitation [66]. Although progress has been made toward
understanding the genetic underpinnings of childhood asthma [123], the task of identifying
the genes contributing to asthma’s missing heritability and linking associated genes to dis-
ease mechanisms still remains. The current paper strives to address these goals through
the recognition that many genotype to phenotype associations remain undetected because
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GWAS only map to trait measurements at a single time point. By using TESL, we were
able to identify genomic regions that would not have been detected with traditional statisti-
cal methods by exploiting the information contained in the trajectory of phenotype values.
In addition, the positive associations we identified using TESL were linked to statistically
significant changes in the trajectory of the FEV1 trait in patients with different alleles, and
in several cases these associations were cis eQTLs, with different alleles showing different
patterns of gene expression.
We demonstrated several methodological advantages to TESL. First, using this method
with longitudinal measurements, we were able to leverage the joint effects of SNPs across
time and increase our power to identify associations that could not be identified using either
conventional univariate regression or standard lasso. Second, by identifying positive associa-
tions that correspond to allelic differences in a d-trait, the dynamic trait association analysis
provides some insight into the potential function of associations. For example, we identi-
fied several positive associations between genetic loci and a relative decrease in the value of
the FEV1, suggesting that the associated genetic region was involved in the development of
increased airway obstruction and worsening asthma.
In addition, the quantity of genome-wide genotype data available for analysis continues to
increase. Current datasets contain millions of SNPs, more densely sampled from the genome
than ever before. However, many of the SNPs are in LD with each other, and thus are highly
correlated. In our model, we use the lasso (l1 penalty) to encourage sparsity in the selected
predictors. However, while lasso is known to perform well in high-dimensional settings where
there is minimal correlation among predictor variables [14,191,171], it has been shown that
it can be unstable when a high degree of correlation exists. This means that when two
predictors are highly correlated, lasso cannot distinguish between them, leading to issues
of repeatability and generalizability [185]. This is potentially problematic for association
analyses where there is a preference for large numbers of correlated SNPs that allow for
increased precision in mapping associations to particular regions of the genome.
For this particular analysis, we made several modifications to the original data set in
order to avoid any stability problems caused by the structure inherent in the data. We
first pruned the SNPs in LD. However, the disadvantage associated with heavily pruning
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SNPs is that it becomes more difficult to map associations to a particular location of the
genome and reduces the overall likelihood of identifying potentially causative SNPs. Thus,
to increase the number of SNPs we include in our analysis, we create multiple data sets of
the same chromosome, each data set containing near independent SNPs. Moving forward,
investigating how to account for this structure in the model and algorithm would contribute
significantly to achieving robust and generalizable association results that may be replicated
in similar populations.
Finding associations between genetic variants and phenotypic measurements given the
high-dimensional nature of GWAS data is a challenging problem. While the strength of the
method presented is the ability to accommodate d-traits, there are also certain limitations.
For example, similar to other GWAS methods, we assume a common disease, common variant
model. Thus, we are limited to markers with a MAF>5%. Future work should address how
to increase the sensitivity of the algorithm to detect rare variants in a setting where dynamic
trait data is available. A second limitation is that a d-trait may be influenced by multiple
genetic loci, each having different types of trajectories in its genetic effect on the d-trait,
such as a mixture of cyclic and linear genetic effects on d-traits. In such a case, the local
autoregressive model would capture only the mixture of different types of genetic effects, and
TESL would not be able to separate the different types of genetic effects. A third limitation
is that our model assumes the d-trait measurements and the SNP effects on these d-traits
are synchronized in time across subjects. As longitudinal data collected for one individual
can be shifted in time compared to the data for a different individual, it is important to
take into account such shifts during analysis. Future work can also address whether using
higher order autoregressive models would be advantageous for this application. A method
that can overcome these limitations and reliably detect d-trait associations will be key to
understanding the genetic basis of d-traits.
In conclusion, we have introduced a novel method for identifying associations between
genetic loci and d-traits that vary over time. We have also demonstrated through simulations
that the d-trait method has a low type I error rate and higher power to detect significant asso-
ciations than lasso or univariate regression methods. Finally, we applied the d-trait method
to a population of children with persistent asthma and identified several loci associated with
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allelic differences in FEV1 trajectories over time. Multiple loci were also associated with
statistically significant allelic differences between levels of gene expression. Thus, we be-
lieve this method represents a new standard for association analysis of longitudinal dynamic
traits.
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8.0 CONCLUSIONS
8.1 SUMMARY
In this thesis, we introduced an integrative computational framework that may be used
to identify complex disease endotypes. We began by using cluster analysis to define five
endotypes among children with mild-moderate asthma using a selected set of clinical traits.
We next explored the relationship between these endotypes and levels of gene expression in
CD4+ T-lymphocytes, and found a set of genes with expression patters that were closely
associated with our endotypes, particularly the degree of atopy present. We grouped this set
of genes into highly correlated modules, and found that one module could be used to predict
the degree of atopy present in an independent cohort of asthmatic patients. Within this
module, we also identified a common motif corresponding to a common regulatory molecule.
Finally, among our endotypes, we found that there was one that was strongly linked to low
lung function. To further investigate the genetic basis of this endotype, we used a novel
method to identify genetic associations with this longitudinal trait. We identified several
novel and confirmatory associations, and found that several associations were ( cis)-eQTLs,
corresponding to changes in gene expression that varied among subjects with different alleles.
Our results support the use of an integrative computational framework to identify endo-
types of complex diseases. We have developed predictive models that defines discrete patient
subsets with unique clinical attributes, discrete clinical trajectories, and variable responsive-
ness to anti-asthma controller medications. Recognition of these endotypes and their clinical
relevance should motivate novel strategies in both the research and clinical settings. Though
asthma has long been recognized as a clinically and etiologically heterogeneous disorder, our
results, together support the presence of no more than 5-6 asthma phenotypic clusters, and
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suggest that the heterogeneity is perhaps not as daunting as previously anticipated. The
observed between-cluster differences in the prevalence of specific environmental and genetic
factors suggest that important etiological differences underlie the configuration of different
asthma phenotypic clusters. Integration of gene expression profiles and genetic data al-
lowed us to identify multiple genes and genetic variants with plausible links to molecular
mechanisms underlying asthma pathogenesis. Thus, in addition to helping inform clinical
management, these integrated multivariable phenotypic classification schemes should help
accelerate research efforts in defining the molecular and environmental underpinnings of this
complex airways disease.
8.2 FUTURE DIRECTIONS
Moving forward, it will be necessary to validate the findings described in this thesis. Al-
though we identified several clinical asthma endotypes in a large cohort of asthmatic children,
prospective validation will be necessary before this framework is ready for widespread use
in the clinical setting. Further validation of gene expression and genetic endotypes will also
need to be performed in larger and more heterogeneous populations. In addition, further
investigation of genetic variants and gene expression profiles corresponding to different endo-
types should be performed to identify common regulatory molecules as potential novel drug
targets.
The integrative computational framework described in this thesis suggests the possibility
that multiple types of data may one day be incorporated into routine clinical care. In order
for this to happen, it will be crucial to develop user-friendly, web-based applications that can
be administered and interpreted easily. In clinic visits, patients specific clinical information
could be obtained from clinicians, along with genetic and gene expression profiles. Targeted
software could be used to assign patients to specific disease endotypes based upon this infor-
mation, and everything could be integrated into the EMR for appropriate risk-stratification
and selection of customized pharmacologic treatments. Such a program could move us closer
to a more efficient and personalized model of medical practice.
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